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Opioids are widely used in the treatment of pain; however, the development of tolerance 
and dependence limit clinical use. The co-administration of a µ opioid receptor (MOR) agonist 
with a δ opioid receptor (DOR) agonist or antagonist produces analgesia with reduced tolerance 
and dependence. Elucidating how MOR and DOR interact has the potential to change opioid 
analgesic treatment.  
This work has two branches: firstly, cyclic MOR agonist/DOR antagonist peptides were 
synthesized. Models of MOR and DOR indicate that the active state conformation of both 
receptors is narrower than the inactive conformations. DOR has bulkier residues occluding its 
binding pocket; the active and inactive state conformations of DOR are narrower than their MOR 
counterparts. Increased steric bulk prevents binding to the active state conformation of DOR and 
is tolerated in the more open MOR active and DOR inactive conformations, producing MOR 
agonist/DOR antagonist ligands. Analogues were synthesized with bulkier residues and both the 
size and stereochemistry of the cycle were varied to explore the active and inactive state MOR 
and DOR conformations. The structure activity relationships found in the cyclic ligands were 
then translated to linear peptides, as they are easier to synthesize and have higher yields. 
However, the flexibility of the linear peptides allowed for more compact binding poses, resulting 
in MOR/DOR agonist ligands. Promising ligands from both series were glycosylated for 
improved bioavailability. Secondly, selective fluorescent MOR agonist and DOR antagonist 
ligands were synthesized and used as probes to explore MOR trafficking in response to DOR and 
DOR antagonists. The presence of both receptors in the same cell did not alter the trafficking of 
agonist-bound MOR or antagonist-bound DOR when only one ligand was present. The presence 
of both ligands in cells that expressed both receptors increased the internalization of agonist-
bound MOR, without changing the trafficking of antagonist-bound DOR. Internalization of 
MOR is involved in receptor recycling and can lead to an increase in surface expressed receptor. 
By increasing surface expression of MOR, antagonist-bound DOR may reduce the development 






1.1 Opioids and the Opioid Receptors 
Opioid analgesics, such as opium and morphine, are among the world’s oldest known 
drugs for the treatment of acute and chronic pain and morphine and other opioid compounds are 
still widely used in the clinic today. Opioids are also prescribed as cough suppressants and 
antidiarrheals, in spite of the fact that many opioids are known to show euphorigenic and 
rewarding properties. Opioid compounds fall into two main structural categories: small molecule 
alkaloids, such as morphine and oxycodone, and opioid peptides, such as the enkephalins, 
endorphins, and dynorphins, all of which interact with the same binding site deep within the 
transmembrane helix bundle of the opioid receptors. Although successful use of opioids in pain 
management is common, there are several side effects, such as constipation and respiratory 
depression, which can severely limit their clinical utility. To make matters more difficult, both 
acute and chronic use of opioids can result in neurochemical adaptations which alter the subject’s 
homeostasis; two noteworthy adaptations caused by opioid use are tolerance, which can occur 
with both acute and chronic use, and dependence, which, in a clinical setting, is primarily seen in 
long term pain management. Tolerance is an adaptation that results in the clinical efficacy of a 
given dose decreasing over time or, in other words, needing an escalating dose to achieve the 
same effect. Dependence is characterized by an alteration of homeostasis, whereby subjects 
require the presence of drug to maintain a “normal” state and the removal of drug results in a 
series of negative symptoms known as withdrawal. These adaptations not only complicate dosing 
regimens for patients and limit the clinical use of opioids, but have been linked to increased 
addiction liability and may contribute to the prevalence of opioid abuse [1-3]. 
Opioid compounds exert their analgesic and rewarding properties through interaction 
with the opioid receptors found in the brain and spinal cord [4]. Opioid receptors belong to the 
Class A family of G protein-coupled receptors (GPCRs); GPCRs are membrane bound proteins 
containing seven transmembrane helices, with the N-terminus in the extracellular space and the
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 C-terminus in the intracellular space. All GPCRs couple with heterotrimeric guanine nucleotide 
binding proteins (G proteins) which are composed of an α subunit and a  and  subunit that 
form an obligate dimer. Upon ligand binding to a GPCR, specific conformations of the receptor 
are stabilized, a signal is transmitted from the extracellular space to the intracellular space and 
second messengers are activated to initiate downstream signaling. In the case of agonist binding, 
the “active” conformation(s) of the transmembrane domains of the GPCR are stabilized; the 
“active” state(s) of the GPCR promotes a change in conformation of the nucleotide binding site 
of the associated α subunit of the G protein which favors the exchange of guanosine diphosphate 
(GDP) for guanosine triphosphate (GTP). Upon GTP binding, the “active” form of the α subunit 
is stabilized; this allows for dissociation of the 
G protein from the receptor as well as the 
dissociation of the α subunit from the  
subunit. These subunits go on to affect 
downstream signaling partners and alter cell 
signaling. Eventually the signal is terminated 
by hydrolysis of GTP to GDP, either through 
the intrinsic GTPase activity of the α subunit or 
through the enzymatic activity of cellular 
GTPase activating proteins (GAPs). This 
allows for the re-association of the α and  
subunits with each other and the receptor, 
resetting the system for further signaling 
(Figure 1.1). The signal can be terminated 
either by the removal of the ligand from the 
extracellular space or by the inactivation of the 
receptor through phosphorylation, 
desensitization, and internalization. 
There are three classical types of opioid receptor – µ, , and κ (MOR, DOR, and KOR 
respectively) – that couple mainly to the adenylyl cyclase inhibitory Gαi/o subfamily of G 
proteins that stimulate inwardly rectifying K
+
 and reduce the opening of voltage gated Ca
+
 
Figure 1.1: GPRC Cycle – Upon agonist binding 
the “active” form of a GPCR is stabilized. This 
stabilizes the “active” state of the associated G 
protein. The “active” G protein conformation favors 
the exchange of GDP for GTP. This allows for the 
dissociation of the G protein subunits from each 
other and the receptor to interact with downstream 
effectors. The signal is terminated by the hydrolysis 
of GTP to GDP which allows for the re-association 
of the G protein subunits with each other and the 
receptor, resetting the system for further signaling. 
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channels, dampening the firing of neurons; the G subunits associated with the opioid receptors 
signal to downstream effectors and alter the signaling of many pathways, including the MAPK 
pathways [5-9]. All three opioid receptors are distributed widely throughout the body; however 
the analgesic and rewarding properties of opioids are primarily centrally mediated. MOR is 
found mainly in the cortex, striatum, thalamus, and locus coeroleus, DOR is found in the 
striatum and cortex, and KOR is found in the limbic regions of the brain and spinal cord [4, 10]. 
As will be discussed more in section 1.3, it is worth noting that MOR and DOR occupy similar 
regions of the brain, especially regions associated with pain signaling, reward, and addiction 
[11]. 
Agonists for MOR, DOR, 
and KOR each display distinct 
pharmacological profiles (Table 
1.1); clinically used opioids are 
MOR agonists.  MOR agonists 
uniformly display analgesic 
properties and produce unwanted 
side effects such as respiratory depression and constipation, though these attributes are 
sometimes utilized in the form of cough suppressants or antidiarrheals; many MOR agonists are 
also euphorogenic. Tolerance develops for all of these properties, though at differing rates; 
normally tolerance develops first to the analgesic and euphoric properties of opioids, while 
tolerance to constipation or respiratory depression is slower to emerge [12]. This poses a major 
problem for chronic use of opioids as a given dose will become less effective in pain 
management, or, in the case of opioid abuse, less effective in providing a high, but remain potent 
in its ability to repress respiration and gastric transit. In contrast, DOR agonists are not used 
clinically, nor are they abused. While DOR agonists are capable of producing mild analgesia, 
DOR agonists also produce seizures [13]. KOR agonists are also somewhat analgesic, but, 
unfortunately, are also dysphoric, sedating, and may produce psychomimetic effects, and 
therefore they are not used clinically in pain management [14].  
As described above and shown in Table 1.1, opioid receptors display a wide range of 
pharmacological responses which often vary depending on the conditions under which the 
in vitro Pharmacology µ δ κ
Antinociception + +/- +/-
Respiratory Depression + - -
Rewarding Effects + - -
Dependence + - +/-
Tolerance + + +
Opioid Receptor
Table 1.1: In vitro Pharmacology of Opioid Receptors – A 
summary of the actions of agonists at the three classical opioid 
receptors. (Levitt unpublished.) 
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, etc) than gene cloning would suggest. It has been proposed that this increased 
number of apparent opioid receptor subtypes – as defined by altered ligand binding, efficacy, 
trafficking, etc – can be explained by opioid receptor/receptor interactions either with other 
opioid receptors or with other non-opioid GPCRs [15]. It has been suggested that homo- and 
hetero-oligomers regulate GPCR ligand binding and pharmacology, the association of 
downstream signaling partners, amplification of signal, and even trafficking and expression of 
receptors [16-24]. Some groups even feel that oligomerization, usually dimerization, is necessary 
for normal opioid function and that opioid dimers are the native receptor state, as opposed to the 
classical view of a GPCR monomer coupling to single G protein to transmit a signal (Figure 1.1) 
[15, 25-30]. The idea of requisite Class A GPCR oligomerization is highly controversial,
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especially as it relates to in vivo function. While there exists a plethora of indirect evidence 
suggesting that dimers or higher order oligomers do occur [24] there are also reports of 
functional monomeric GPCRs [31-33].  
1.2 Theories of Tolerance 
The development of tolerance with chronic use of opioid analgesics is a major problem 
facing clinical use. This is particularly problematic as patients often develop tolerance to the 
analgesic properties of opioids long before they develop tolerance to unwanted side effects, such 
that in order to achieve the desired analgesic effect one risks major complications, as described 
in section 1.1. The cellular mechanism(s) for the development of analgesic tolerance are unclear; 
however there are several hypotheses to explain this phenomenon. 
Opioid receptors, like all GPCRs, are expressed on the plasma membrane of cells such 
that their binding sites are accessible to the extracellular matrix; many opioid ligands, such as 
endogenous opioid peptides, are unable to cross the plasma membrane and so the ligand binding 
site must be surface accessible in order for opioid receptors to be activated. After agonist binding 
and initiation of downstream signaling, opioid receptors are phosphorylated at serine or 
threonine residues on the intracellular C-terminal tail by various kinases. This prevents G 
proteins from accessing the receptor, thus preventing further signal transduction; receptors in this 
                                                 
1
 Oligomerization of other classes of GPCRs, such as Class C receptors, is well established. 
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state are said to be desensitized, as they can bind ligand, but this does not produce a transduction 
of signal. This phosphorylation also marks the receptors for recognition by  arrestins which 
induce internalization of the receptor via clatherin coated pits, sequestering them in vesicles 
inside the cell [34-37]. One theory addressing the development of tolerance suggests 
internalization of the targeted receptor produces tolerance by removing receptors from the cell 
surface rendering the receptor unable to bind extracellular ligand and initiate downstream 
signaling [2]. Internalization depletes the cell’s receptor reserve (number of receptors expressed 
on the surface but not actively used in signaling at any given time) and so a given amount of 
drug will stimulate fewer receptors and produce less of an effect than it did prior to receptor 
internalization, in other words, producing tolerance. Receptor binding studies have shown that 
MOR surface expression decreases after chronic treatment with MOR agonists and that there is a 
corresponding loss of opioid mediated signal [38-40]. 
The degree of receptor reserve for a given ligand may be important in the development of 
tolerance. Ligands with high intrinsic efficacy will have a large receptor reserve as a single 
binding event may be able to trigger many second messenger signaling events. This means that 
fewer receptors need to be occupied to produce a given level of response; so a smaller percentage 
of the total receptor population will be lost when agonist bound receptors are desensitized or 
internalized. As a result, there will be a larger store of unoccupied receptors to take the place of 
the desensitized or internalized receptors – a receptor reserve – and so tolerance will be slower to 
develop. Ligands with lower intrinsic efficacy will have a smaller receptor reserve as more 
receptors will need to be occupied to produce a given response, so when the agonist occupied 
receptors are desensitized or internalized a smaller percentage of the total receptor population 
will remain active, and tolerance will develop more quickly. This theory is supported in the case 





(DAMGO) and fentanyl are slow to develop analgesic tolerance [40, 41], whereas lower efficacy 
agonists, such as morphine, rapidly develop tolerance [42, 43]. 
Another theory suggests that receptor endocytosis is the first step in resensitization of the 
receptor and that tolerance emerges from desensitization via phosphorylation while receptor is 
still on the cell surface. Here, after agonist binding and phosphorylation, the receptors are 
internalized, re-sensitized through dephosphorylation and recycled to the surface in a functional 
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state [36, 40, 44]. This idea is supported by the fact that some MOR agonists, such as DAMGO 
and fentanyl, undergo robust internalization, but are slow to develop analgesic tolerance [40, 41], 
whereas morphine, in many systems, does not undergo internalization, but rapidly develops 
tolerance [42, 43]. This would suggest that morphine binds ligand and the receptor is 
phosphorylated and desensitized, but the receptor conformation that is stabilized by morphine 
does not undergo internalization. This would leave non-functional receptor on the plasma 
membrane and reduce the overall number of functional receptors on the cell surface, leading to 
tolerance as described above. In the case of DAMGO or fentanyl, the receptor conformation that 
is stabilized is capable of undergoing internalization and can therefore be dephosphorylated and 
returned to the surface in a functional state, maintaining surface expression of functional 
receptors. 
Whether internalization causes or helps prevent the development of tolerance, the 
trafficking of MOR to and from the plasma membrane seems to play a key role. Exploring the 
relationship between altered opioid trafficking and the development of tolerance will lay the 
groundwork for a better understanding of opioid signaling and the development of better opioid 
analgesics with extended clinical use. In this work I will develop mixed efficacy ligands and 
explore how various ligand combinations alter the trafficking of MOR and DOR in live cell 
systems, monitored with fluorescently tagged ligands and receptors. 
1.3 DOR Modulation of MOR Tolerance 
1.3.1 DOR Antagonists 
It is well established that the analgesic effects of opioids and the tolerance to opioid 
analgesia are both mediated through MOR. However, it has been shown that MOR does not act 
in isolation in vivo or in vitro; of particular note are the ways in which MOR and DOR have been 
shown to interact [45]. It has been demonstrated that the co-administration of a MOR agonist and 
a DOR antagonist mitigates the development of tolerance and dependence, while preserving the 
desired analgesia [46-49]. The role of DOR blockade in the development of MOR tolerance and 
dependence is of significant clinical importance, as it could potentially extend the use and reduce 
the abuse of opioid drugs. The role of DOR itself, as opposed to DOR ligands, in the 
development of MOR tolerance has also been explored; it has been shown that the knock-down 
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or knock-out of DOR in mice slows the development of tolerance to a MOR agonist [50, 51]. 
Taken together, these data strongly suggest that there is a clinically significant interaction 
between the two receptors, MOR and DOR, which modulates the development of tolerance to 
and dependence on MOR agonists. Several theories have been proposed to explain how a DOR 
antagonist can decrease the development of tolerance to MOR agonists, two of which involve 
MOR/DOR heterodimers (Figure 1.2). One theory proposes that upon DOR antagonist treatment 
DOR surface expression is increased, either through blockade of basal DOR signaling such that 
 
Figure 1.2: Mechanisms by which Opioid MOR/DOR Heterodimers may Effect Receptor Trafficking – 
Mechanisms by which DOR receptor blockade may regulate the surface expression of MOR via MOR/DOR 
heterodimers. (A) MOR/DOR heterodimers expressed on the cell surface are not internalized with DOR 
antagonist is bound. (B) DOR antagonists act as molecular chaperones which facilitate trafficking of MOR/DOR 
heterodimer to the cell surface from the endoplasmic reticulum. (C) DOR antagonists block basal DOR signaling 
on the cell surface. The cell increases trafficking of MOR/DOR heterodimers to the cell surface from the 
endoplasmic reticulum to maintain enkephalinergic tone. 
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the cell traffics more DOR to the surface from intracellular stores to maintain enkephalinergic 
tone or through molecular chaperoning which stabilizes the receptor and enhances trafficking to  
the surface of the cell from the endoplasmic reticulum [52, 53]. MOR is then co-trafficked to the 
plasma membrane in the form of a MOR/DOR heterodimer from the endoplasmic reticulum or 
vesicular stores, thereby making more MOR binding sites available on the plasma membrane and 
preventing the development of tolerance through loss of cell surface binding [15, 54]. Another 
hypothesis proposes that if MOR/DOR heterodimers occur on the plasma membrane, antagonist 
bound DOR will prevent the internalization of agonist bound MOR through their 
receptor/receptor dimerization, thereby maintaining surface expression of MOR [28].  These 
theories are supported by the fact that MOR and DOR have been shown to co-localize in the 
same cell in the dorsal root ganglion [55-57], a region associated with pain signaling. There also 
exists a third set of possibilities which do not involve the dimerization of MOR and DOR: it is 
possible that MOR and DOR signal to a central location, either inter- or intracellularly, and the 
confluence of these signals attenuates the development of tolerance and dependence. It is likely 
that these signals would alter the trafficking pattern of the receptors, but do not necessarily do so 
through a direct physical interaction between MOR and DOR. Regardless of the mechanism, it is 
clear that DOR antagonists have the ability to modulate the activity and function of MOR ligands 
as well as the ligand-receptor interactions and trafficking patterns of MOR. 
1.3.2 DOR Agonists 
Endorphins and enkephalins are the body’s endogenous MOR and DOR agonist peptides; 
though endorphins and enkephalins are referred to as MOR and DOR ligands respectively, they 
are somewhat promiscuous and both groups of peptides are capable of stimulating both MOR 
and DOR. This may have clinical significance, as it has been shown that the co-administration of  
DOR agonist with a MOR agonist lessens the development of tolerance to and dependence on 
MOR agonists, as well as reducing the incidence of other unwanted side effects [58-60] without 
affecting MOR mediated analgesia. It has also been demonstrated that sub-analgesic doses of 
DOR agonists potentiate the affinity and antinociceptive potency of MOR agonists in a dose 
dependent manner [59, 61-63]. While these are intriguing observations, they have been pursued 
less vigorously than MOR agonist/DOR antagonist interactions, perhaps because of the severe 
unwanted effects which can result from stimulation of DOR by some non-endogenous ligands, 
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such as mood alteration, convulsions, and seizures [13], all significant drawbacks for any chronic 
therapeutic. 
1.4 Multifunctional Ligands as Tools to Explore MOR/DOR Interactions 
It has been recognized that the simultaneous modulation of multiple targets often 
generates a more desirable drug profile, in some cases even reducing the development of 
negative side effects [64-68]. Given the data presented above in section 1.3.1, the idea of mixed 
efficacy ligands displaying MOR agonism/DOR antagonism has been the object of much 
investigation, both as leads for new analgesics and as tools to illuminate the mechanism(s) by 
which DOR influences the development of MOR tolerance.  It is possible that these novel 
ligands might not only affect neurochemical adaptations involving analgesic tolerance and 
dependence, but also the emergence of negative side effects such as constipation and respiratory 
depression or tolerance to these effects [14, 66]. This has generated a whole new field of research 
directed toward developing novel mixed opioid efficacy ligands, as opposed to new formulations 
of multiple pre-existing drugs. Such a multifunctional ligand would possess considerable 
advantages over the traditional approach of using a combination of selective opioid drugs; 
combination therapies often contain active ingredients with differing pharmacokinetic properties 
which complicate dosing regimens and reduce patient compliance. Complicated drug cocktails 
also increase the risk of patient to patient variation in efficacy and adverse drug reactions. As a 
result, many groups have investigated the development of mixed efficacy ligands, both peptidic 
and non-peptidic, displaying varying degrees of MOR and DOR agonism or antagonism [69-75]. 
These compounds fall into two main categories: bivalent ligands, in which two separate 
pharmacophores, in this case a MOR agonist pharmacophore and a DOR antagonist 
pharmacophore, are linked by a flexible spacer [75-77], and bifunctional ligands, which contain a 
single set of binding elements which can interact with both targets, in this case the MOR agonist 
binding site and the DOR antagonist binding site [72, 73] (Figure 1.3).  
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Peptides provide a convenient starting point for the development of multifunctional 
opioid ligands to study the interactions between MOR and DOR. Many endogenous and 
synthetic opioid peptides have been studied and their structure-activity relationships (SAR) have 
been well characterized, providing the foundation for applying rational design to existing ligands 
to explore the MOR and DOR active (agonist) and inactive (antagonist) binding pockets. 
Peptides also possess the distinct advantage of making multiple contacts within the receptor 
binding site which can be easily modified by making minor alterations to the constituent 
residues; this allows for the fine tuning of binding and efficacy profiles and greater flexibility in 
ligand generation. Additionally, most peptides are unable to cross the plasma membrane; as we 
are interested in the trafficking of MOR and DOR to and from the cell surface knowing that the 
ligand-receptor interaction occurs at the plasma membrane will help to elucidate at what point in 
the receptor trafficking cycle a ligand produces its effect. 
1.5 Objectives 
The development of tolerance to the analgesic properties of opioids is a major problem 
facing the clinical use of opioids and may contribute to the development of physical dependence 
on opioids, a risk factor for abuse and addiction [1-3]. Although the mechanism(s) by which 
altered opioid trafficking are linked to the development of tolerance are unclear, it is well 
Drug Cocktail Bivalent Ligand Bifunctional Ligand 




(A) (B) (C) 
 
Figure 1.3: Drug Cocktail vs. Bivalent Ligands vs. Bifunctional Ligands – (A) A drug cocktail containing two 
selective drugs with distinct pharmacophores (B) A bivalent ligand in which two separate pharmacophores are 
connected by a flexible linker to form a single molecule (C) A bifunctional drug in which two separate 
pharmacophores are merged into a single ligand which displays properties of both pharmacophores. 
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established that both acute and chronic tolerance to opioid agonists is concomitant with altered 
opioid receptor trafficking [38-40].  
My thesis project takes two different approaches to explore the development of tolerance 
to and dependence on opioid analgesics. The first branch aims to develop mixed efficacy 
MOR/DOR ligands that display reduced development of tolerance and dependence. In Chapter 2, 
I will explore the development of cyclic mixed efficacy ligands displaying MOR agonism and 
DOR antagonism with similar affinity for both MOR and DOR, with selectivity relative to KOR. 
In Chapter 3 I will translate these ligands to linear scaffolds to simplify the structures in an effort 
to increase yields and ease purification. The second branch explores how various ligand 
treatments alter the trafficking patterns of MOR and DOR in live cell systems to determine if 
ligand profiles which slow the development of tolerance and dependence display distinctive 
receptor trafficking. I will attempt to relate patterns of receptor co-trafficking to the development 
of tolerance and dependence. In Chapter 4, I will use fluorescent ligands and fluorescently 
tagged receptors to explore how different drug cocktails alter the trafficking pattern of receptors 
in live cell systems which express both MOR and DOR. In Appendix B, I will utilize the 
fluorescent ligands developed in Chapter 4 to explore the necessity of receptor dimerization for 
basic opioid function using receptors isolated in high density lipoprotein (HDL) discs and design 
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Cyclic Mixed Efficacy Ligands 
 
2.1 Introduction 
The recognition that a specific receptor often plays a pivotal role in a disease state shifted 
the drug discovery paradigm toward a “one disease, one target” approach. The driving force 
behind this shift was the idea that the more specific a drug, the fewer negative side effects it will 
elicit. However, it has since been recognized that the simultaneous modulation of multiple 
targets often generates a more desirable drug profile, in some cases even reducing the 
development of negative side effects [1-3]. As described in Chapter 1.3, this concept is 
illustrated in the field of opioid analgesics, where the co-administration of a mu opioid receptor 
(MOR) agonist with a delta opioid receptor (DOR) antagonist provides all the expected analgesia 
of a MOR agonist, but with reduced negative side effects, especially reduced tolerance and 
dependence liabilities [4-8], features that limit the clinical use of opioid analgesics [10]. As a 
result, the idea of bifunctional mixed efficacy ligands displaying MOR agonism/DOR 
antagonism has been the source of much investigation, both as leads for new analgesics and as 
tools to illuminate the mechanism(s) by which DOR ligands influence the development of MOR 
tolerance. 
Our lab and others [7, 8, 10-18] have explored the development of bifunctional mixed 
efficacy ligands where MOR agonist activity is combined with DOR antagonism in the same 
molecule using a “merged” pharmacophore  [2]. Such a multifunctional ligand would possess 
considerable advantages over the traditional approach of using a combination of selective opioid 
drugs with possibly differing pharmacokinetic or pharmacodynamic properties, as described in 
Chapter 1.4. Peptides provide a convenient starting point for the development of multifunctional 
opioid ligands. The synthetic ease with which peptide sequences may be altered and the wealth 
18 
 
of knowledge about opioid peptide structure-activity relationships provide the foundation for 
applying structure based design to existing compounds directed toward exploring the MOR and 
DOR binding pockets. In addition, peptides are generally larger molecules and make many 
contacts within the binding pocket; this allows for multiple sites of alteration to fine tune the 
binding and efficacy profiles of the resultant ligands to achieve balanced binding to both 
receptors and full MOR efficacy and functional DOR antagonism. Previous work in our lab 
resulted in a lead peptide MP-143 (MP compounds were synthesized by Maggie Przydzial) with 
a linear sequence of Tyr-DCys-Phe-Phe-Cys-NH2, cyclized through a disulfide bridge between 
the D-Cys in position 2 and the L-Cys in position 5, hereafter denoted with c(S-S) with the 
cyclized residues in square brackets (e.g. Tyr-c(SS)[DCys-Phe-Phe-Cys]NH2) [20]. Peptide MP-
143 displays full agonism
2
 at MOR and slightly reduced efficacy at DOR as well as high affinity 
for both receptors (Table 2.1). Since MP-143 has appreciable DOR efficacy, we then focused 
our efforts on designing ligands that retain MOR agonist activity, but with reduced stimulation of 
DOR [7]. Using our receptor models for both active, or agonist binding, and inactive, or 
antagonist binding, states of MOR and DOR [7, 10, 21-25] we predicted that adding bulky 
aromatic substituents in the third or fourth position of peptide MP-143 would produce a steric 
clash in the DOR active state binding site which would not be seen in the DOR inactive site, thus 
favoring binding to the DOR inactive state and consequently resulting in lower DOR efficacy 
[7].  Docking to corresponding active and inactive state MOR models revealed no analogous 
receptor state-specific adverse interactions; we therefore predicted that increasing steric bulk at 
position 3 or 4 would provide the desired MOR agonist/DOR antagonist profile.  It is important 
to note that these models of the active and inactive conformations of the opioid receptors are 
based on crystal structures of antagonist bound receptors; there are no crystal structures for the 
active conformations of the opioid receptors. More detail can be found in Section 2.5.8. 
Incorporation of 1-Nal (1-naphthylalanine) or 2-Nal (2-naphthylalanine) into position 3 
or 4 of MP-143 did indeed yield analogs with high MOR/ low DOR efficacy, but all analogs also 
retained high kappa opioid receptor (KOR) affinity [7]. Such KOR activity is less than desirable; 
while KOR agonists are known to be effective against mild pain, they are also known to cause 
dysphoria and other psychomimetic effects, which severely limits their usefulness [26]. The 
                                                 
2
 N.B. In this work “agonism” and “efficacy” refer to the ability of compounds to stimulate G protein turnover in the 
GTPγS assay. Details can be found in Section 2.5.7. 
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compounds discussed in this chapter make 
further use of our receptor-ligand models to 
design analogues that maintain high affinity for 
both MOR and DOR, but not KOR, and 
display full MOR agonism and DOR 
antagonism. 
2.2 Development Cyclic Pentapeptide MOR 
Agonist/DOR Antagonist Ligands 
To understand the basis for the relatively high 
KOR binding affinity of MP-143 and related 
compounds in the series [20] we docked MP-
143 to our previously developed active state 
model of KOR [25, 27]. The docking suggested 
an important role for Phe
4
 of MP-143 in 
interacting with KOR. An improved active state model generated from the recently released 
crystal structure of KOR [28] demonstrates that Phe
4
 of MP-143 indeed can form  - stacking 
interactions in the KOR active site with Tyr
219
 from extracellular loop 2 located at the beginning 
of helix 5 (Figure 2.1). These interactions likely contribute to the binding and agonist character 
Figure 2.1: Modeling of peptide MP143 in the 
KOR Active Site – MP143 (Tyr-c(S-S)[DCys-Phe-
Phe-Cys]NH2) docked in the KOR active state 
model. Highlighted is the π-π interaction between 
Phe
4
 of MP143 with Tyr
219
 of KOR (shown by dots). 
This favorable interaction appears to contribute to 
the high affinity of MP143 for KOR as well as its 
agonist character.  
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate. Cyclization abbreviated as SS for 
disulfide linkage, nd = not determined, dns = does not stimulate. 
 
Sequence











nd 47±9 nd nd nd
100±10>10001.7± 0.31.6±0.1
0.6±0.1 1.3±0.4 >1000 64±6
ndndnd103±1.5nd
3.0±0.6 86±7 2.6±0.1 dns nd
1.3±0.7
1.5±0.7 0.3± 0.2 >1000 93±4
74±139.6 ± 4.2100± 0.5>10002.0±0.8
80± 4 74 ±17
nddns6.4±3.8
8.6±0.5 77±9 1.4 ± 0.8 69± 1.6 45 ± 9
Efficacy
0.3± 0.2 0.8± 0.3
Binding (nM)
MOR DOR KOR
Table 2.1: Non-Aromatic Phe
4
 Replacements in Cyclic Mixed Efficacy Pentapeptides 
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of peptide MP-143. DOR and MOR lack a corresponding aromatic residue in the binding site – 
DOR has a Ser
206
 and MOR has a Thr
225
 in the analogous position. We hypothesized that 
changing the Phe
4 
of peptide MP-143 to a non-aromatic hydrophobic residue would eliminate 
this favorable aromatic interaction with Tyr
219
 and thus decrease affinity to KOR. As shown in 
Table 2.1, replacing Phe
4
 of peptide MP-143 with the aliphatic residues Leu, Ile, or Nle resulted 
in the predicted decreased binding to KOR (Table 2.1). 
As all three analogues with an aliphatic residue in position 4 displayed similar opioid 
profiles, high affinity and efficacy for MOR and DOR with low KOR activity, we chose, for 
convenience, to carry forward analogs containing the Nle
4
 substitution. Since cyclic opioid 
pentapeptides with either D- or L-stereochemistry in residue 5 displayed similar MOR and DOR 
affinities in the initial examples of this series [20], we also examined the opioid profile of LP-08, 
the D-Cys
5
 diastereomer of LP-09 (LP compounds were synthesized by Lauren Purington).  This 
analog displayed a similar binding profile as LP-09, but with somewhat reduced efficacy at both 
MOR and DOR (Table 2.1).  Thus, we chose both LP-09 and LP-08 as starting points for 
modifications to reduce DOR efficacy.  
To achieve this, we 
again relied on our 
previously described 
receptor models [7, 10, 21-
25] that suggested that 






 of the ligands would 
better fit the large and 
more open antagonist 
binding pocket of the 
receptors in the inactive 
state, while having steric 
clashes in the more narrow 
agonist binding pocket of 
Figure 2.2: Modeling of the Inactive and Active Conformations of MOR 
and DOR – (A) the inactive conformation of MOR bound to the MOR 
antagonist β-Funaltrexamine, (B)  the active conformation of MOR bound to 
the MOR agonist JOM6 [9], (C) the inactive conformation of DOR bound to 
the DOR antagonist naltrindole, (D)  the active conformation of DOR bound 
to the DOR agonist JOM13 [19]. The edges of the binding pockets are shown 
with dashed lines. For both MOR and DOR the active conformation of the 
receptor is narrower than the inactive conformation. 
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the active receptor 
conformation (Figure 2.2). A 
greater effect was expected for 





,  and 
Trp
284
 – occluding the ligand 







 –  at 
the corresponding positions.  
Examination of our current, 
refined models of DOR and 
MOR in complex with MP-143 
supported our previous 
suggestions (Figure 2.3). Of 
particular importance here is 
the observation that Phe
3
 of 
peptide MP-143 is in close 
proximity to Met
199
 in the DOR agonist binding pocket. (Figure 2.2A) However, in the DOR 
antagonist binding conformation (Figure 2.2B), Met
199
 is angled away from the ligand, enlarging 
the binding pocket. Replacing the Phe
3
 of peptide MP-143 with a larger residue would be 
expected to increase the steric clash between the ligand and the active conformation of DOR, 
disfavoring the binding of the ligand to the active conformation and thus reducing its agonist 
character, as we have observed before [10]. However, due to the presence of the smaller side 
chain of Thr
218
 in the MOR binding pocket (Figure 2.2C) instead of Met
199
 in the DOR binding 
pocket, adding steric bulk in the 3 position of peptide MP-143 should have less of an effect on 
MOR efficacy. Consequently, we prepared and pharmacologically assessed a series of 
pentapeptides based on LP-09 and LP-08, in which the Phe
3
 residue was replaced by 1-Nal or 2-





 analogs of LP-08 and LP-09 were synthesized and are shown in 
Table 2.2; replacing the Phe
3
 of LP-08 or LP-09 with 2-Nal (analogues LP-17 and LP-21) 
greatly reduces efficacy at both MOR and DOR, consistent with our earlier observations [7], 
Figure 2.3: Modeling of MP143 in the MOR and DOR Active and 
Inactive Binding Pockets – MP143 (Tyr-c(S-S)[DCys-Phe-Phe-
Cys]NH2) docked in the active and inactive state models of DOR (A and 
B) and MOR (C and D). Docking of MP143 to the active state of DOR 
shows a steric clash between Phe
3
 of MP143 and Met
199
 of DOR, 
highlighted by an arrow in 2A; this steric clash is not seen when MP-
143 is docked in the DOR inactive state binding site or the MOR active 
or inactive state binding sites.  
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while also greatly reducing affinity at DOR.  By contrast, the 1-Nal
3
 analogues JPAM3 (SS) and 
JPAM2 (SS) display a more promising profile in which DOR efficacy is more selectively 
affected and DOR affinity is less drastically reduced.  In these analogues the DCys
5
 diastereomer 
exhibits a greater ability to reduce efficacy than the corresponding LCys
5
, but this effect is 
equally expressed at MOR and DOR.   
In compounds JPAM3 (SEtS) and JPAM2 (SEtS) we examined the effect of increasing 
the ring size of the 14-membered disulfide scaffold of JPAM3 (SS) and JPAM2 (SS) to a 16-
membered ethylene dithioether-containing cycle, an approach we have often used to modulate 
opioid activity [7, 20, 27].   In the present case increasing the cycle size had little effect on 
binding affinity or efficacy, with the exception of a rather large reduction in maximal stimulation 
at MOR (51% vs. 100% stimulation relative to the standard, DAMGO) and a slight increase in 
KOR affinity displayed by JPAM3 (SEtS) compared to JPAM3 (SS).   
Sequence





















7.3±1.4 64±8 nd nd3.1± 0.04 29±4 >1000 38.6 ± 3.4 25±13
36±547±4>100058±88.6±1.4
dns nd dns nd
ndnd300 ±10011±8
2.7±0.3 4.0±0.5 >5000 dns nd
3.4± 0.894±1>500011±34±2
dns nd <10 nd
nd30±8nd17±2
1.4±0.4 23± 2.9 770±140 30.5±1.2 34±13
8.3±1.351±6180±9037.0±1.51.3±0.1
dns nd <10 nd
nd<10440±11024±1
1.4±0.3 56±2.5 >1000 43.0±2.7 17.5±5.0
nd9.3±0.9>1000>10002.1±0.9
32±11 nd dns nd
nddnsnddns
2.4±1.3 240±70 >1000 25±1 nd
0.7±0.3 12±2.7 730±330 100±2 5.1±1.4 22±0.9 160± 70 <10 nd
Binding (nM) Efficacy
MOR DOR KOR
Table 2.2: Bulky Aromatic Phe
3
 Replacements in Cyclic Pentapeptides 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate. Cyclization abbreviated as SS for 




Of these analogues, the most promising is JPAM3 (SS) which possesses high MOR 
affinity, full agonist behavior at MOR in this assay and greatly reduced DOR efficacy (22% of 
DOR standard DPDPE). Furthermore, JPAM3 (SS) lacks the undesired KOR activity, which 
makes it a promising ligand for the exploration of functional MOR/DOR interactions. However 
JPAM3 (SS) displays ~18 fold lower affinity at DOR compared to MOR. The C-terminal 
carboxylic acid analogues of the carboxamide terminal peptides described above were designed 
to restore a balance in MOR and DOR affinity, as negatively charged C-terminal groups often 
interfere with MOR binding [29]. As seen in Table 2.2, the carboxy-terminal analogs displayed 
the expected decrease in MOR affinity, decreased KOR affinity, but little significant effect on 
DOR binding.  Peptide JPAM1 (SS) was an exception, in that DOR affinity improved 
approximately 14-fold compared with JPAM2 (SS) (Ki = 4 nM vs. 56 nM). Both disulfide-
containing, C-terminal carboxylic acids, LP-32 and JPAM1 (SS), display the desired binding 
profile: high affinity for MOR and DOR, low affinity for KOR.  The dithioether-containing 
analogs, JPAM4 (SEtS) and JPAM1 (SEtS) have less desirable binding profiles displaying 
somewhat lower and/or less balanced MOR and DOR affinity and reduced MOR efficacy.   
Examination of the 
efficacy profiles of LP-32 and 
JPAM1 (SS) reveals an 
interesting observation.  While 
LP-32, like its carboxamide 
terminal counterpart JPAM3 
(SS), is a full agonist at MOR, 
with low partial DOR agonism 
(~20% maximal stimulation vs. 
DPDPE), peptide JPAM1 (SS), 
which differs from LP-32 only 
in the stereochemistry of the C-
terminal Cys, acts as an 
antagonist at both MOR and 




-containing analogs is a consistent feature among the 
compounds shown in Table 2.2; however the complete elimination of MOR efficacy for JPAM1 
Figure 2.4: Comparison of LP-32 and JPAM1 (SS) in the MOR 
Active and Inactive Binding Sites – (A) LP32 (Tyr-c(SS)[DCys-1-
Nal-Nle-Cys]OH) docked in the active state model of MOR and (B) 
JPAM1 (SS) (Tyr-c(SS)[DCys-1-Nal-Nle-DCys]OH) docked in the 
inactive state model of MOR. The C-terminal COO- of LP-32 forms a 
favorable ionic interaction with Lys
303
. However, when JPAM1 (SS) is 
docked in the active site the C-terminal COO- is angled toward Glu
229
, 





 relieves this repulsion and allows a 
favorable interaction with Lys
233




(SS) was unexpected. An explanation for this behavior can be deduced from examination of LP-
32 and JPAM1 (SS) docked to the active and inactive states of MOR.  Figure 2.4A depicts LP-
32 bound to our model of the MOR active receptor.  In this model, the C-terminal COO
-
 of LP-
32, while being close to Glu
229
 from transmembrane helix 5, may also form an ionic bridge with 
the positively charged side chain of Lys
303
 from helix 6.  This ionic bridge can be formed only in 
MOR and only in the active conformation, but not in DOR or KOR which have Trp
284
 (DOR) or 
Glu
297
 (KOR) in the corresponding position in helix 6. The favorable ionic interactions of LP-32 
in the agonist binding pocket of MOR may explain its behavior as an efficacious MOR agonist. 
The unfavorable ionic interaction between the C-terminal carboxylate of LP-32 and Glu
229
 from 
helix 5 in MOR or Glu
297
 from helix 6 in KOR is consistent with the 6- and 7-fold decreased 
affinity of LP-32 to MOR and KOR, respectively, as compared to JPAM2 (SS) with a C-
terminal amide.  For JPAM1 (SS), the change in stereochemistry of residue 5 orients the 
terminal COO
-
 away from Lys
303
 and toward Glu
229
, resulting in an unfavorable ionic repulsion. 










 pair from helix 5 and can form favorable ionic interactions with Lys
214
 in the inactive 
receptor conformation. These ligand-receptor interactions help explain the antagonist activity of 
JPAM1 (SS) in MOR and its improved binding and antagonist activity at DOR. 
Two of the ligands described in this series, JPAM3 (SS) and LP-32, displayed 
nanomolar binding to both MOR and DOR with selectivity relative to KOR. These ligands 
displayed high efficacy at MOR with reduced DOR efficacy, making progress towards achieving 
our goal of developing a potent mixed efficacy MOR agonist/DOR antagonist ligand. Both 
ligands, however, display appreciable DOR agonist character and a slight preference for binding 
to MOR over DOR. We next sought to further reduce this DOR agonist activity and to balance 
the binding between MOR and DOR by exploring a new tetrapeptide scaffold. 
2.3 Development Cyclic Tetrapeptide MOR Agonist/DOR Antagonist Ligands  
Previous work in our lab generated a series of cyclic tetrapeptide ligands which display 
MOR agonist and DOR antagonist character, with low nanomolar affinities for both receptors. 
This series is similar to the pentapeptide series described above in that it is composed of cyclic 
ligands with hydrophobic residues between the bridging thiol containing amino acids. However, 
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in place of DCys
5
 in the pentapeptide series described above, ligands in this series contain a D-
penicillamine (DPen) and one less residue within the cycle (Table 2.3). One of the ligands in this 
series, KSK-102, displayed well balanced MOR and DOR binding, with moderate efficacy at 
MOR and slightly reduced efficacy at DOR. Because of its promising profile, KSK-102 has been 
modified with a C-terminal β-glucoserine, in which the side chain hydroxyl of Ser is covalently 
O-linked to a β-glucose, hereafter referred to as “glucoserine” (VRP-26). This modification was 
made to improve stability and bioavailability after peripheral administration [30-32]. (KSK 
compounds were synthesized by Katarzyna Sobczyk-Kojiro and VRP compounds were 
synthesized by Vanessa Porter-Barrus) While the addition of a glucoserine reduced MOR and 
DOR affinity somewhat, it also improved the overall in vitro drug profile in two key ways: it 
drastically improved selectivity relative to KOR and significantly reduced DOR efficacy, 
rendering the ligand a DOR antagonist. We have tested VRP-26 in the warm water tail 
withdrawal assay in mice (data not shown); VRP-26 produced dose-dependent antinociception 
after peripheral administration, demonstrating that it is able to cross membranes to reach its site 
of action in the CNS.  
VRP-26 provides proof of concept that our potent mixed efficacy opioid ligands are 
effective at producing antinociception after peripheral administration. These ligands address the 
problems of residual DOR efficacy and unbalanced MOR/DOR binding found in the 
pentapeptide series described above. There is, however, room for improvement in the ability of 
these ligands to stimulate MOR; VRP-26 only displays partial agonist behavior at MOR, a more 
Table 2.3: Development of Bioactive Cyclic MOR Agonist/DOR Antagonist Ligands 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate. Cyclization abbreviated as SMeS for 











15 ± 5 2.6±1.4 56±37 nd nd
21.5± 0.4332±2812±11.33±0.06
4.7 ± 0.3 4.7 ± 0.1 55 ± 7
nddnsnddns41±6






efficacious agonist with similar potency would likely require smaller doses to achieve the same 
analgesic effect, further limiting the development of tolerance and dependence, as these negative 
adaptations occur in a dose dependent manner. I therefore designed and synthesized a series of 
analogues containing various aromatic residues in the third position cyclized through either a 
methylene or ethylene dithioether bridge (Table 2.3). 
As described above in Chapter 2.2, we have utilized our homology models to 
approximate how a representative cyclic ligand, MP-143, fits in the active and inactive sites of 
MOR and DOR. We found that the active sites of both MOR and DOR are narrower than their 
inactive counterparts, and that increased steric bulk reduces efficacy, with a greater effect seen at 
DOR than MOR. We hypothesized that the hydrophobic bulk and conformational restriction of 
Aci in KSK-102 and VRP-26 played a role in the decreased efficacy at MOR; the 
conformational restriction of Aci kinks the peptide backbone of KSK-102 somewhat and likely 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate. Cyclization abbreviated as SMeS for 
methylene dithioether linkage and SEtS for an ethylene dithioether linkage, nd = not determined, dns = does not 
stimulate. 
 
Table 2.4: Flexible Hydrophobic Aci
3
 Replacements in Cyclic Tetrapeptides 
Sequence



















32±2 34±10 15±3 nd1.8±0.1 2.38±0.05 79±6 30±2 30±7
440±7086±5>50004.2±0.34.7±1.3
13±8 nd dns nd
nddns200±9525±3
0.48±0.08 1.0±0.1 9.2±2 60±3 0.3±0.1
0.73±0.0373±55.3±1.21.0±0.30.39±0.03
dns nd <10 nd
nd<1028±1850±8
0.49±0.09 1.9±0.3 33±14 87±4 1.0±0.05
27±221±27±1.80.73±.0.040.22±0.02
22± 3 nd nd nd
nd<109±718±3
0.67±0.02 2.77±0.09 >1000 95 ± 4 4.7±0.9
1.1±0.632±27.4±0.60.4±0.10.29±0.03
73±1 1.0±0.3 dns nd
nd<10nddns






makes it more difficult for it to fit into the narrower active conformation of MOR. I therefore 
replaced the Aci
3
 of KSK-102 with various bulky but flexible aromatic residues and then 





 side chains. By making both the methyl and ethyl bridged compounds we 
were able to further explore how the angle of the side chain in the third position and of the ligand 
as a whole in the active site affected binding and efficacy to MOR and DOR. The binding 
affinities and efficacies for this series are listed below in Table 2.4. 




, ethyl bridged analogue (JH6) displayed 




, analogues (JPAM13) it was the methyl bridged 
compound that displayed the desired profile (JH compounds were synthesized by Jeff Ho). To 
explain the large difference in MOR efficacies that relatively small changes in cycle size and 
steric bulk in the first position make, we again turned to our homology models. We found that 
the cycle size (methyl vs. ethyl bridged) greatly affects the angle of the side chain in the first 
position and that the added bulk of the two methyl groups in Dmt can produce a steric clash in 
the active site of MOR, reducing efficacy. When comparing JH6, JPAM13 SMeS, and JPAM 








 in MOR 
and that the distance between these residues is larger in the inactive conformation than in the 
active conformation of the receptor (Figure 2.5).  In order to accommodate the extra bulk of the 
two methyl groups of Dmt
1
 the ligand as a whole must tilt to fit into the narrower active site; as 
these ligands are 
conformationally 








SEtS, tilt of Dmt
1
 
is different due to 
its interaction with 
Figure 2.5: Comparison of JH6 and JPAM13 (SEtS) in the MOR Active Site – 
(A) JH6 (Tyr-c(SEtS)[DCys-Hfe-DPen]NH2) and (B) JPAM(SEtS) (Dmt-
c(SEtS)[DCys-Hfe-DPen]NH2) in th e active state model of MOR. The 2,6 methyl 
groups of Dmt
1




 of MOR in the active 
conformation (highlighted with arrows). The steric clash reduces the affinity of 
JPAM13 (SEtS) for the active conformation of MOR, reducing its ability to 
stimulate the receptor. 
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SMeS or SEtS groups, respectively. The larger cycle size produces a steric clash in the active site 
of MOR between Dmt
1
 of the ligand and Tyr
148
 of the receptor, reducing MOR efficacy, while 
the smaller cycle size allows the Dmt
1
 to tilt such that it can fit in the MOR active site, granting 
higher efficacy. However, JH6, which contains a Tyr
1
, has reduced steric bulk as compared to 
JPAM13 SEtS, and so there is less of a steric clash in the active conformation of the receptor, 
allowing for full MOR agonist behavior (Figure 2.5).  
The most promising ligands, JH6 and JPAM13 (SMeS) both contained a homo-
phenylalanine (Hfe) residue as the aromatic amino acid in the third position. This fits with our 
hypothesis that a flexible but bulky side chain within the cyclized portion of the molecule would 
balance high MOR efficacy with low DOR efficacy, while preserving binding affinity at both 
receptors. As these ligands possess the desired binding and efficacy profiles, they present an 
opportunity to generate a bioavailable mixed efficacy peptide. I therefore modified both of these 
sequences with a C-terminal glucoserine to yield compounds JPAM18 (SEtS) and JPAM19 
(SMeS). Both of these glycosylated ligands displayed promising binding profiles, however, their 
efficacy profiles were less than ideal. JPAM 19 (SMeS) displayed partial agonism at both MOR 
and DOR and was discarded as a viable in vivo ligand. JPAM18 (SEtS) displayed full MOR 
agonism, but, unfortunately, also displayed partial DOR agonism and low potency at both 
receptors, unlike its unglycolsylated counterpart JH6. To more fully explore Hfe
3
 analogues 
JPAM18 (SMeS) was also synthesized, but could not be tested due to solubility issues. 
2.4 Conclusions   
 The studies discussed in this chapter were aimed toward developing opioid 
ligands that display high affinity and efficacy for MOR, high affinity and low efficacy for DOR 
and low affinity for KOR as tools for exploring MOR/DOR interactions and the development of 
tolerance to and dependence on opioid analgesics.  Using our validated receptor models of the 
active and inactive states of all three receptors for structure-based design, we were able to 
achieve this goal by selectively modulating the affinity and efficacy of our lead peptide MP-143. 
First, examination of docking of the lead peptide, MP-143, to active state KOR suggested the 
participation of the ligand’s Phe
4
 residue in an aromatic  interaction unavailable in MOR or 
DOR.  Replacement of this Phe
4
 with an aliphatic residue achieved the desired result of greatly 
reducing KOR affinity and efficacy.  Next, predicted differences in ligand docking to the DOR 
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active and inactive conformations were exploited by incorporating bulkier residues in the third 
position of peptide MP-143 to favor binding to the DOR inactive conformation.  As predicted, 
the use of bulky aromatic groups within the cyclized portion of the peptide
 
greatly reduced DOR 
efficacy.  Of our pentapeptide analogs, JPAM3 (SS) and LP-32 in particular, with 1-Nal
3
, 
exhibited the desired profile of high MOR/ low DOR efficacy; among the tetrapeptide analogues 
those with a flexible Hfe residues in the third position, JH6 and JPAM13 (SMeS), displayed the 
desired binding and efficacy profiles in vitro. Unfortunately, the addition of a C-terminal 
glucoserine significantly altered the binding, efficacy, and potency of the resulting compounds, 
JPAM18 (SEtS) and JPAM19 (SMeS). These ligands are being set aside for now, though future 
directions may include the exploration of other glycosylation alternatives which move the sugar 
away from the opioid pharmacophore, with the goal of maintaining the desired pharmacological 
profile.  Such glycosylation alternatives may include using a lactose instead of a glucose, 
conjugation through a Thr as opposed to Ser, or extension of the sugar away from the main 
peptide either through a homo-serine or by incorporating Gly before the C-terminal glycosylated 
amino acid. Arginine and homo-arginine analogues of promising sequences will also be 
synthesized as a means of improving bioavailability, as Arg rich peptides also show improved 
membrane penetration [33]. Future work may also include Tyr
1
 replacements to explore how the 
removal of the 2, 6 dimethyl groups of Dmt effect the efficacy of ligands in this series. 
The wide range of affinity and efficacy shown by the closely related analogs in Table 2.2 
and Table 2.3 reflects both the structural sensitivity of the ligand-receptor interaction and the 
utility of peptides, whose structures can be easily and subtly manipulated for probing the details 
of the ligand-receptor interaction.  Of particular note is the profound functional difference 
observed for LP-32 and JPAM1 (SS), which differ only in stereochemistry of the C-terminal 
residue and which possess similar affinity, but quite different efficacy profiles. Similar effects 
can be seen the tetrapeptide series, as with JPAM10 (SEtS) and JPAM11 (SEtS) which differ 
only in the connectivity of the napthyl ring in the third position. This ligand pair also display 
similar binding profiles, but have profoundly different MOR and DOR stimulation.  
The results reported here further validate our receptor models and our approach of using 
these models for rational design to exploit differences in the opioid receptors highly homologous 
binding pockets. We have demonstrated that we can successfully generate MOR agonist/DOR 
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antagonist ligands using information from our models and that we can fine tune our binding and 
efficacy profiles in predictable ways. While we have not generated a glycosylated ligand with 
which to explore in vivo activity in this series, we have designed several mixed efficacy tools 
which can be used to probe the in vitro pharmacology of tolerance.  
The most promising ligands from this series will then be carried forward into in vivo 
studies. Literature precedent states that the co-administration of a MOR agonist with a DOR 
antagonist limits the development of tolerance, dependence, and self-administration, features that 
limit the clinical use of opioid analgesics [4-8], but we have not yet confirmed if our mixed 
efficacy ligands also display these desirable properties. We will, therefore, test the ability of our 
most promising mixed efficacy ligands to produce both acute and chronic tolerance, physical 
dependence, and conditioned place preference. 
 
2.5 Methods and Materials 
2.5.1 Materials 
All reagents and solvents were purchased from commercial sources and used without further 
purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. Louis, 
MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue culture 
reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). Radioactive 
compounds were purchased from Perkin-Elmer (Waltham, MA, USA). Peptide synthesis 
reagents, amino acids, and Rink resin were purchased from Advanced Chem Tech (Louisville, 
KY, USA). Wang resins were purchased from Nova Biochem, EMD (Gibbstown, NJ, USA). 
Fmoc-Ser (b-GlcAc4)-OH (the glycosylated serine building block) was synthesized by Larisa 
Yeomans accordingly to previously published protocols  [34]. 
2.5.2 Solid-Phase Peptide Synthesis  
Peptides were synthesized using standard solid phase Fmoc 
(fluorenylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Synthesizer (CS Bio 
Company, Menlo Park, CA, USA), using previously described protocols. [35] C-terminal amide 
peptides were synthesized using Rink resin, C-terminal acid peptides were synthesized using 
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Fmoc-Wang resin preloaded with the C-terminal amino acid. A 20% solution of piperidine in N-
methyl-2-pyrrolidone (NMP) was used to remove the first Fmoc protecting group before 
synthesis and again to remove the Fmoc-protecting group after each coupling cycle. Coupling 
was performed using a four-fold excess of amino acid and a solution of 0.4 M 
hydroxybenzotriazole (HOBt) and O-benzotriazole-N,N,N',N'-tetramethyl-uroniumhexafluoro- 
phosphate (HBTU) in dimethylformamide (DMF), in the presence of diisopropylethylamine 
(DIEA). After the synthesis was complete, the resin was washed with NMP, then with 
dichloromethane, and dried under vacuum. The peptides were cleaved from the resin and side-
chain-protecting groups removed by treatment at room temperature for 2 h with a cleavage 
cocktail consisting of 9.5 mL trifluoroacetic (TFA) acid, 0.25 mL triisopropylsilane (TIS) and 
0.25 mL H2O. The solution was concentrated in vacuo, and peptides were precipitated using 
cold, fresh diethylether. The filtered crude material was then purified using a Waters 
semipreparative HPLC (Waters Corporation, Milford, MA, USA) with a Vydac Protein and 
Peptide C18 column, using a linear gradient 10% Solvent B (0.1% TFA acid in acetonitrile) in 
Solvent A (0.1% TFA acid in water) to 60% Solvent B in Solvent A, at a rate of 1% per minute. 
The identity all peptides were determined ESI-MS performed on an Agilent Technologies 
LC/MS system using a 1200 Series LC and 6130 Quadrupole LC/MS (Agilent Technologies, 
Santa Clara, CA, USA) in positive mode with 50–100 µL injection volume and a linear gradient 
of 0% Solvent D (0.02% TFA and 0.1% acetic acid (AcOH) in acetonitrile) in Solvent C (0.02% 
TFA and 0.1% AcOH in water) to 60% Solvent D in Solvent C in 15 min. The purity of all 
peptides was determined using a Waters Alliance 2690 Analytical HPLC (Waters Corporation, 
Milford, MA, USA) and Vydac Protein and Peptide C18 reverse phase column, using a linear 
gradient of 0–70% Solvent B in Solvent A at a rate of 1% per minute. Linear peptides were 
purified to ≥ 95% purity by UV absorbance at 230 nm. 
2.5.3 Disulfide Cyclization of Linear Peptides 
Pure linear disulfhydryl-containing peptide was dissolved at 1mg/mL in argon saturated 
solution of 1% (v/v) AcOH in H2O at 4C. The pH of the peptide solution was raised to 8.5 using 
NH4OH, followed by the addition of 4 molar equivalents of K3Fe(CN)6. The reaction mixture 
was stirred on ice, under argon for two minutes and quenched by addition of glacial acetic acid to 
pH 3.5. The reaction mixture was incubated with 100-200 mesh anion exchange resin AG-3-X4 
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(Biorad, Hercules, CA, USA) and swirled occasionally at room temperature until the solution 
was colorless. The crude mixture was then filtered, concentrated in vacuo, and purified to ≥98% 
purity as determined by UV absorbance at 230 nm as described above to yield the disulfide 
linked cyclized peptides. The identity of cyclic peptides was determined by ESI-MS as described 
above. 
2.5.4 Dithioether Cyclization of Linear Peptides 
A DMF solution of the linear peptide (15 mg/40 mL) containing 5 molar equiv of 1,2-
dibromoethane was added dropwise to a round-bottom flask containing 10 molar equiv of 
potassium tert-butoxide in 100 mL of anhydrous DMF saturated with argon, on ice. The reaction 
was stirred for 2 h under argon, on ice, and then quenched with to pH 3.5 with glacial acetic acid. 
Solvents were removed in vacuo, and the residue was purified to ≥ 98% purity as determined by 
UV absorbance at 230 nm as described above to afford the alkyl dithioether cyclized peptide. 
The identity of cyclic peptides was determined by ESI-MS as described above.  
2.5.5 Cell Lines and Membrane Preparations  
C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid 
receptor [36] and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) 
opioid receptor [37] were used for all in vitro assays. Cells were grown to confluence at 37ºC in 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with 
ice cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). 
Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 
150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200xg for 3 min. The 
cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized with a 
Tissue Tearor (Biospec Products, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The 
homogenate was centrifuged at 20,000xg for 20 min at 4 C, and the pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The 
final pellet was resuspended in 50mM Tris-HCl and frozen in aliquots at -80ºC. Protein 




2.5.6 Radioligand Binding Assays 
Opioid ligand-binding assays were performed using competitive displacement of 0.2 nM 
[
3
H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane preparations 
containing opioid receptors. The assay mixture, containing membrane suspension (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine, and various concentrations 
of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. 
The samples were rapidly filtered through Whatman GF/C filters  using a Brandel harvester 
(Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl buffer. The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, 
Waltham MA, USA). Nonspecific binding was determined using 10 μM naloxone. Ki values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
data using GraphPad Prism version 5.01 for Windows. The results presented are the mean ± 
standard error from at least three separate assays performed in duplicate. 
2.5.7 Stimulation of [
35
S]GTPγS Binding  
Agonist stimulation of [
35
S] guanosine 5'-O-[gamma-thio]triphosphate ([
35
S]GTPγS, 
1250 Ci, 46.2TBq/mmol) binding was measured as described previously [38].  Briefly, 
membranes (10-20 μg of protein/tube) were incubated 1 h at room temperature in GTPγS buffer 
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [
35
S]GTPγS, 30 μM 
guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation 
of [
35





enkephalin  (DAMGO) at MOR, D-Pen
2,5
- enkephalin (DPDPE) at DOR, or U69,593 at KOR. 
The reaction was terminated by rapidly filtering through GF/C filters and washing ten times with 
GTPγS buffer, and retained radioactivity was measured as described above.  The results 
presented are the mean ± standard error from at least three separate assays performed in 






2.5.8 Opioid Receptor Modeling  
The homology modeling of opioid receptors in complexes with peptide ligands was 
performed as previously described [7, 10, 39]. The procedure included the following steps: 1) 
residue substitution in corresponding structural template(s); 2) rigid body helix movement to 
reproduce structural rearrangement during receptor activation observed in crystal structures of 
rhodopsin and adrenergic receptor; [40] 3) peptide ligand docking in accordance with 
mutagenesis-derived constraints; and 4) refinement of receptor-ligand complex using distance 
geometry and energy minimization with CHARMm. The validity of this modeling procedure has 
been assessed in blind prediction experiments of structural modeling of MOR, [7, 10] A2a-
adenosine receptor, [41] CXCR4, and D3 dopamine receptor [39] performed before the release 
of the corresponding crystal structures. The following comparison with experimental structures 
showed relatively high accuracy of our homology models: rmsd were between 1.5 and 2.5 Ǻ for 
seven transmembrane helices [39, 41]. A comparison of our previously developed opioid 
receptor models [7, 10, 25, 27] and recently released crystal structures of the mouse MOR [42] 
and the human KOR  [28] demonstrated the high reliability in prediction of ligand-receptor 
interactions in the more conserved “message” region located deeply in the ligand binding pocket, 
and less precise modeling in the “address” region of flexible extracellular loops which are 
responsible for ligand selectivity. Despite some inaccuracies, the previous models suggested the 









side chains, respectively, and aromatic interactions between pentapeptide Phe
4
 side chain and 
residues from the extracellular loop 2. [7, 8, 25, 27] Here we used X-ray structures of MOR 
(PDB ID: 4dkl) and KOR (PDB ID: 4djh) to refine the models of MOR and KOR complexes 
with antagonists, especially in the variable loop regions, and to develop the homology model of 
antagonist-bound conformation of the human DOR (UniProt ID: P41143, residues 46-333). 
Further, we used the crystal structure of the human KOR (PDB ID: 4djh) together with our 
previous models of active conformations of opioid receptors [7, 10] for modeling of the active 
conformations of MOR, DOR, and KOR, which are appropriate for agonist docking. Low-energy 
conformations of cyclic pentapeptides were generated using previously developed 
pharmacophore models of tetrapeptides [43] with additional conformational search in the region 
of the fifth residue and disulfide bridge. Coordinates of MOR (active and inactive states), DOR 
35 
 
(inactive state), and KOR (active state) with peptide 1 can be downloaded from our web site 
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Linear Mixed Efficacy Ligands 
3.1 Introduction 
Many of the negative side effects associated with opioid analgesic use, such as tolerance 
to and dependence on opioid compounds, are closely tied to their mechanism of action; in fact, as 
discussed in Chapters 1.1 and 1.2, both the analgesia associated with opioids and the 
development of tolerance and dependence are primarily modulated through the mu opioid 
receptor (MOR). In Chapters 1.3, 1.4, and 2, we examined how mixed efficacy opioid ligands 
with MOR agonism and delta opioid receptor (DOR) agonism [1-4] or antagonism [5-9]  display 
reduced tolerance and dependence liabilities as compared to conventional opioid analgesics, 
while maintaining the analgesia expected of MOR agonists. As discussed in Chapter 2.3, our lab 
has had success in developing cyclic mixed efficacy MOR/DOR tetrapeptides [8, 10, 11]. The 
best compounds from that series, KSK-102, JH6, and JPAM13 (SMeS), displayed low 
nanomolar affinity for MOR and DOR, with selectivity relative to the kappa opioid receptor 
(KOR), and moderate to high efficacy at MOR and little to no stimulation of DOR (Table 2.3) 
(KSK and JH compounds synthesized by Katarzyna Sobczyk-Kojiro and Jeff Ho respectively).  
While these peptides display our desired binding and efficacy
3
 profiles, we anticipated 
that they would make poor drug candidates not only because their synthesis is low yielding, but 
also because they are peptides. Peptides are particularly susceptible to enzymatic degradation 
and often have low membrane permeability and therefore low bioavailability [12-14]. This is 
particularly problematic for opioid peptides as they must cross membranes in the digestive tract 
and the blood brain barrier (BBB) to be orally active in the central nervous system (CNS), where 
opioids exert their analgesic properties [15-17]; in fact BBB penetration is considered one of the 
biggest hurdles that needs to be overcome to have viable peptide therapeutics [18, 19]. While this
                                                 
3
 N.B. In this work “agonism” and “efficacy” refer to the ability of compounds to stimulate G protein turnover in the 
GTPγS assay. Details can be found in Section 3.5.6. 
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 may seem to argue against using peptides as the basis for effective pain treatment, peptides do 
offer an array of unique opportunities. Peptides have a high density of chemical information, 
making many ligand-receptor contact points, allowing for the fine tuning of binding and efficacy 
profiles for multiple targets, a key advantage in mixed efficacy ligands. Additionally, peptides 
are broken down into smaller peptide fragments and amino acids after metabolism and 
degradation; this means that the incidence of negative off target effects due to active metabolites 
is lessened for peptide therapeutics relative to their small molecule counterparts. It is also worth 
noting that in the case of opioid peptides we already have well characterized structure-activity 
relationships (SAR) and good lead compounds for drug development, especially for mixed 
efficacy MOR/DOR ligands.  
In an effort to make out peptide ligands more “druggable” we planned to use the peptide 
ligands developed in this chapter as the basis for blood brain barrier (BBB) penetrating 
glycosylated peptides, an approach which has been convincingly demonstrated by Polt and 
coworkers in the field of mixed efficacy opioid ligands  [4, 14, 20, 21] and which we have 
ourselves tested in the cyclic tetrapeptide series described in Chapter 2.3. Literature precedent 
and our own initial attempts at glycosylated peptides (see KSK-102 and VRP-26 in Chapter 2.3, 
VRP compounds synthesized by Vanessa Porter-Barrus) predict that these glycopeptides will 
have increased membrane permeability and CNS activity relative to their parent compounds, 
without greatly altering the binding or efficacy profiles of the resultant ligands. We are therefore 
incorporating a C-terminal serine residue as a site for sugar modifications and plan on testing the 
glucoserine analogues, where the Ser is covalently O-linked to a β-glucose, of the most 
promising peptides described below for in vivo activity in the future.  
As described in Chapter 2, we have had success in developing potent mixed efficacy 
opioid ligands [8, 10, 11]. However, to date all of these ligands have been cyclic in nature. A 
long-time focus in our lab has been on cyclic peptides as a means to improve receptor selectivity 
by “freezing out” unwanted conformations; for mixed efficacy ligands conformational restriction 
may not be advantageous. Furthermore, the synthesis of linear peptides involves fewer chemical 
modifications and purifications while also providing higher yields than cyclic ligands. 
Consequently, we shifted our focus to examine linearized versions of previously described MOR 
agonist/DOR antagonist cyclic peptides [22] and explored the effect of phenylalanine 
41 
 
replacements on agonist activity to determine if the SAR found in cyclic peptides [8, 11] is 
mirrored in linear analogues. In parallel, we also used the known linear opioid agonist peptides 
developed by Roques, Tyr-DThr-Gly-Phe-Leu-X-NH2, where X = DSer (DTLES) or X = DThr 
(DTLET) [23], as templates for installing the Phe replacements to modulate efficacy in a manner 
similar to that found in our cyclic analogues. Although initially reported as DOR selective, 
DTLES and DTLET actually bind to both MOR and DOR with similar affinity and display 
some selectivity relative to KOR [14]. In this chapter we will make a two series of analogues 
based on our previously described cyclic series and the Roques compounds in an effort to make 
linear mixed efficacy MOR agonist/DOR antagonist ligands. 
3.2 Direct Translation of Cyclic Mixed Efficacy Tetrapeptides to Linear Ligands 
In our first series we sought to directly translate our successful cyclic tetrapeptide, KSK-
102 (Chapter 2.3), into a linear ligand, substituting the DCys
2
 with either a D-Serine (DSer) or 
D-Threonine (DThr) and the DPen
5
 with a D-Leucine (DLeu), thereby removing reactive thiol 
groups, while maintaining similar shape and bulk in the second and fifth positions. For the initial 
sequences in this series we used a Tyr
1
 in place of Dmt
1
 for cost concerns. We hypothesized that 
we would find a ligand which bound tightly to MOR and DOR and stimulated MOR, but not 
DOR, yielding a mixed efficacy MOR agonist/DOR antagonist (Table 3.1). Unfortunately, the 
initial direct translations of KSK-102 (VRP-29 and VRP-31) did not bind to either MOR or 
DOR and were abandoned. However, our models
4
 [8, 22, 24-28] suggested that an L- (as 





 analogue (VRP-35), which did, in fact, display mid-range nanomolar binding to 
MOR and DOR with moderate stimulation of MOR and very low efficacy at DOR (Table 3.1). 
Like its cyclic counterpart, VRP-35 displayed selectivity relative to KOR and no measurable 
KOR agonist activity. There was, however, room for significant improvement in increasing the 
affinity of these ligands for MOR and DOR and, in the case of VRP-35, increasing its ability to 
stimulate MOR. I therefore synthesized a series of ligands with various aromatic and aliphatic 
residues in the third position in hopes of finding a ligand which would make appropriate 
hydrophobic contacts with MOR and DOR, improving binding to both receptors, while 
                                                 
4
 N.B. Models of the opioid receptors are based on X-ray crystal structures of antagonist bound receptor. No crystal 
structures exist for the active conformation of the receptors. For more details see Section 3.5.7. 
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preserving or improving the efficacy profile found in VRP-35; these ligands are listed in Table 
3.1 (HVW compounds synthesized by Helen V. Waldschmidt.)  
While we made several hydrophobic substitutions in the third position, no one compound 
exactly meets our desired profile of nanomolar binding to MOR and DOR while displaying 
agonism only at MOR. In fact, many of the compounds in the series displayed low MOR 
stimulation and poor binding to DOR and/or MOR. However, two compounds stand out as 
different from the rest of the analogues in this series. JPAM7 is unique among the Tyr
1
 
pentapeptide analogues in that it displays nanomolar binding to MOR and DOR, with selectivity 
relative to KOR; this is the only Tyr
1
 compound in the series with single digit nanomolar binding 
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Table 3.1: Direct Linear Translations of Cyclic Tetrapeptides 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 





to MOR and DOR. 
It is also unusual in 
that it also displays 
full DOR agonist 
character; all the 
other compounds in 
this series are DOR 
antagonists or weak 
partial agonists. 
Docking studies of 
JPAM7 in the DOR active site show that the added flexibility of the Hfe
3
 contributes greatly to 
its agonist character and nanomolar binding. All of the other analogues in this series have either 
bulky groups, such as 1- or 2Nal, or inflexible residues like Aci or Idg in the third position; these 
groups produce a steric clash in the DOR active site, reducing efficacy as intended. However the 
side chain of Hfe is flexible enough to assume a conformation which relieves this steric clash, 
allowing the ligand to assume a more compact binding pose to fit into the narrower DOR active 
site. Furthermore, because of this somewhat unique binding position, the Leu
4
 of JPAM7 may 
be able to make some favorable hydrophobic interactions with Trp
284
 in the DOR active site 
which are not seen in the other ligands in this series. The side chain flexibility of Hfe
3
 and the 
narrow binding pose that it produces allows JPAM7 to assume a conformation which fits into 
the binding site of MOR and DOR better than the bulky and inflexible analogues in this series, 
contributing to the tight binding of JPAM7 (Table 3.1; Figure 3.1). 
While JPAM7 is able to assume a more compact conformation than many of the other 
ligands in this series it does not fit well in the MOR active site. Modeling studies show that in 
order for JPAM7 to sit far enough down in the binding pocket of MOR to stimulate receptor 
turnover the Hfe
3
 of JPAM7 forms a steric clash with Trp
308
 in the receptor; DOR has Leu
300
 in 
the corresponding positions which are less bulky and do not produce a steric clash in the DOR 
active site (Figure 3.1). To relieve this clash, the ligand must sit higher in the active site, 
reducing its ability to stimulate MOR. This may explain why JPAM7 displays only partial 
agonism at MOR. 
Figure 3.1: Modeling of peptide JPAM7 in the MOR and DOR Active Sites – 
JPAM7 (Tyr-DThr-Hfe-Leu-Ser-NH2) docked in the active state model of MOR (A) 
and the active state model of DOR (B). The Hfe
3
 of JPAM7 forms a steric clash in the 
MOR active site with Trp
318
 (highlighted by an arrow). This clash is relieved in the 





3.1) also stands out in this 
series, as it actually 
displays the desired 
efficacy profile of MOR 
efficacy coupled with 
relatively low DOR 
efficacy. Modeling studies 
comparing VRP-35 and 
JPAM6 (Figure 3.2), 
show that the two ligands 
assume a similar shape in 
the MOR active site, but that the 1Nal
3
 in JPAM6 forces the ligand into more extended shape 
than VRP-35, which has an Aci in the third position. Because the 1Nal
3
 extends out from the 




 of extracellular loop 2 in the 
MOR active site. Our modeling shows that in an effort to relieve this steric clash the ligand as a 
whole shifts toward helix 5 of the MOR active site  (relative to the position of VRP-35 in the 




. In other 
words, because Aci
3
 is close to the backbone of VRP-35 the ligand assumes a more compact 
shape than other ligands in this series, allowing it to fit more comfortably into the narrow MOR 
active site, contributing to its agonist character. We therefore generated a new analogue, HVW-
1, in which Tyr
1
 of VRP-
35 is substituted with a 
Dmt
1
 in hopes of 
improving binding without 
drastically effecting the 
efficacy profile. HVW-1 
displays a much improved 
binding profile as 
compared to VRP-35, 
however HVW-1 is an 
Figure 3.2: Comparison of VRP-35 and JPAM6 in the MOR Active Site 
– VRP-35 (Tyr-DThr-Aci-Leu-Ser-NH2) (A) and JPAM6 (Tyr-DThr-1Nal-
Leu-Ser-NH2) (B) docked in the active state model of MOR. The Aci
3
 of 
VRP-35 sits close to the peptide backbone, whereas the 1Nal
3
 of JPAM6 
assumes a more extended pose away from the peptide backbone and forms a 




 (highlighted by 
arrows). This clash prevents JPAM6 (and similarly extended analogues) 
from binding to the MOR active site reducing MOR efficacy. 
 
Figure 3.3: Comparison of VRP-35 and HVW-1 in the MOR Active Site 
– VRP-35 (Tyr-DThr-Aci-Leu-Ser-NH2) (A) and HVW-1 (Dmt-DThr-Aci-
Leu-Ser-NH2) (B) docked in the active state model of MOR. The 2,6 methyl 
groups of Dmt
1





 (highlighted by arrows). This clash prevents HVW-1 from 




antagonist at both MOR and DOR. Information from molecular modeling studies suggests that 
the added bulk of the 2, 6 methyl groups on Dmt
1




 in the 
active site of MOR, making HVW-1 a MOR antagonist. As VRP-35 has a Tyr
1
, it fits easily into 
the narrow active site of MOR and displays MOR agonism. (Figure 3.3)  
These same modeling studies suggest that a smaller DSer
2
 may relieve some of this steric 
hindrance and rescue MOR agonist activity. We therefore synthesized a pair of ligands with a 
Dmt
1
 which differ only in the residue in the second position (Table 3.1; Figure 3.4), JPAM12, 
which contains DThr
2
, and HVW-5, which contains a DSer
2
. Both of these ligands display 
nanomolar binding to both MOR and DOR, with some selectivity relative to KOR. JPAM12 is 
an antagonist at both MOR and DOR. The substitution of a DSer
2
 for a DThr
2
 (HVW-5) does, as 
predicted, rescue MOR 
agonist activity. However, 
this substitution also 
confers DOR agonist 
character, resulting in a 
MOR agonist/DOR 
agonist compound. While 
unexpected, this profile is 
still desirable, as is 
discussed in the next 
section. 
3.3 Modifications to Roques Scaffolds to Produce Mixed Efficacy MOR/DOR Ligands 
For our parallel series of linear peptides based on the Roques compounds DTLES and 
DTLET we installed various bulky hydrophobic Phe
4
 replacements with the thought that this 
substitution might selectively confer DOR antagonism as it did in our cyclic ligands described in 
Chapter 2. We initially installed an Aci
4
 in place of Phe
4
 in hopes of mimicking the in vitro 
binding and efficacy profile of KSK-102, unfortunately, this compound, VRP-33, displayed 
micromolar binding to all three opioid receptors. We also made analogues with less constrained, 
bulky hydrophobic residues in the fourth position as we did in the linear series described above; 
their binding and efficacy profiles are listed in Table 3.2. Most of the ligands in this series 
Figure 3.4: Comparison of JPAM12 and HVW-5 in the MOR Active Site 
– JPAM12 (Tyr-DThr-Idg-Leu-Ser-NH2) (A) and HVW-5 (Tyr-DSer-Idg-
Leu-Ser-NH2) (B) docked in the active state model of MOR. The DThr
2
 of 
JPAM12 forms a steric clash in the MOR active site with Val
300
 (highlighted 






display nanomolar binding to both MOR and DOR, with some selectivity relative to KOR, and 
both MOR and DOR agonist activity. It is interesting to note that the ligands with the more 









) displayed significantly lower affinity for MOR and DOR than the other compounds in this 
series, which contained more flexible residues in the fourth position. Despite its relatively poor 
binding, we were able to obtain efficacy data for JPAM16. Perhaps unsurprisingly, JPAM16 is 
the only ligand in this series which displays a MOR agonist/DOR antagonist profile. This is 
likely due to the fact that some conformational restriction is necessary to selectively produce a 
steric clash in the DOR active site to reduce DOR efficacy, without effecting MOR efficacy; 
more flexible residues will be able to assume conformations which can be accommodated in the 
narrower DOR active site and will display DOR agonism. We next attempted to improve the 
binding of JPAM16 by replacing the Tyr
1
 with a Dmt
1
 (JPAM17). While this slight 
modification did produce the expected increase in affinity, yielding a better binding profile, the 
substitution of a Dmt
1
 for a Tyr
1
 also completely abolished MOR efficacy. We saw a similar 
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Table 3.2: Modification of Roques Linear Hexapeptides 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 





effect when we substituted 
a Dmt
1
 for a Tyr
1
 in our 
cyclic series with JH6 and 
JPAM13 (SEtS) and in 
the VRP-35/HVW-1 
ligand pair; binding of the 
Dmt
1
 analogue was 
increased, but MOR 
efficacy was drastically 
reduced. In the case of 
JH6/JPAM13 (SEtS) and 
VRP-35/HVW-1 we 
posited that in order for the phenolic hydroxyl of the Dmt to anchor correctly in the MOR 
binding site the ligand must assume a conformation which causes the 2, 6 methyl groups of the 




. This steric clash is 
relieved in the more open MOR inactive site, allowing for nanomolar binding, but low efficacy 
at MOR. We may be seeing a similar effect with our JPAM16 and JPAM17 ligand pair, where 
the added bulk of the two methyl groups in the first position combined with a DThr
2
 prohibits 
binding to the MOR active conformation, as seen in the linear pentapeptide series described in 
the previous section (Figure 3.5). Whatever the reason, neither JPAM16 nor JPAM17 fit our 
desired profile of nanomolar binding to MOR and DOR, with MOR agonist and DOR antagonist 
behavior.  
While we were not able to selectively reduce DOR efficacy while retaining nanomolar 
binding to MOR and DOR, these hexapeptide ligands remain promising as a MOR agonist/DOR 
agonist profile is also desirable. It has been demonstrated that the co-administration of a MOR 
agonist with a DOR agonist potentiates the binding and antinociceptive potency of MOR 
agonists [1-4]. The synergistic effect between MOR and DOR agonists has been shown to lessen 
the development of tolerance and dependence, as well as other unwanted side effects [4, 14, 29]. 
The Polt group has already successfully developed mixed efficacy MOR agonist/DOR agonist 
peptide ligands, which they report as displaying reduced tolerance and dependence liabilities and 
reduced self-administration [4, 14, 21]. However, when the in vitro pharmacology for the lead 
Figure 3.5: Comparison of JPAM16 and JPAM17 in the MOR Active 
Site – JPAM16 (Tyr-DThr-Idg-Leu-Ser-NH2) (A) and JPAM17 (Dmt-DThr-
Idg-Leu-Ser-NH2) (B) docked in the active state model of MOR. The 2, 6 
methyl groups of Dmt
1





 (highlighted by arrows). This clash prevents 




ligand in this series, MMP-2200, was first published, no efficacy data at KOR was reported, 
though the ligand displayed low nanomolar KOR affinity [4]. We therefore tested this compound 
in our own assays, and found that MMP-2200 displays full agonist behavior at KOR, albeit with 
poor potency. The binding for MMP-2200 at MOR, DOR and KOR was similar to reported 
values, as was efficacy at MOR and DOR. (Table 3.3; MMP-2200 was a kind gift from Dr. 
Robin Polt.) KOR agonists have been shown to cause dysphoria [30] and psychomimetic effects 
[31] and patients describe KOR agonists as unpleasant. For these reasons KOR agonist often 
display aversive effects [32]. These are undesirable characteristics in a drug designed to treat 
chronic pain and often lead to decreased patient compliance. The ligands that I have described in 
this section provide an answer to this problem, in that they not only display a preference for 
binding to MOR and DOR over KOR, but also, for the most part, act as KOR antagonists. The 
lack of KOR activity in the ligands developed in this chapter will help to deconvolute the effects 
that DOR agonists have on MOR agonist behavior and provide a more acceptable drug profile 
for use in human subjects. 
 Of the Tyr
1
 hexapeptide MOR agonist/DOR agonist ligands VRP-39 displays the best 
binding profile, with nanomolar binding to both MOR and DOR and some selectivity relative to 
KOR. We next decided to modify VRP-39 with an N-terminal Dmt to balance the MOR and 
DOR binding (JPAM15). While this modification did balance MOR and DOR binding and 
increase potency at MOR and DOR it also significantly reduced selectivity relative to KOR. 
However, as VRP-39 already displays the desired pharmacological profile, we added a C-
terminal glucoserine improve its bioavailability. The resulting compound, HVW-2, still displays 
the desired binding and efficacy profile (Table 3.2) and will be carried forward into animal 
studies in future work. 
Table 3.3: In vitro Pharmacological Data for MMP-2200 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate, except values denoted with * where n=1. 
Ser(Lac) is a Ser is covalently O-linked to a β-lactose. 
 
Sequence
MOR DOR KOR % EC50 (nM) % EC50 (nM) % EC50 (nM)
MMP-2200 Tyr-D-Thr-Gly-Phe-
Leu-Ser-(Lac)-NH2





3.4 Conclusions   
 The studies discussed in this chapter were aimed toward developing linear mixed efficacy 
opioid ligands displaying MOR agonist and DOR antagonist behavior. Two series of linear 
ligands were developed: a series of pentapeptides designed as linear translations of the cyclic 
tetrapeptides described in Chapter 2.3 with a C-terminal Ser as a handle for sugar modification 
and a series of hexapeptides, also with a C-terminal Ser, based on linear peptides designed by 
Roques [23] and Polt [4, 14, 20, 21]. 
 Most of the analogues synthesized in the pentapeptide series displayed lower affinity for 
MOR and DOR and greater selectivity relative to KOR than their cyclic counterparts described 
in Chapter 2.3. The DThr
2
 analogues in this series also displayed antagonist behavior at both 
MOR and DOR, with VRP-35 and JPAM7 standing out as notable exceptions. Preliminary 
modeling studies suggest that, for the most part, these linear ligands adopt a less compact 
binding pose than their cyclic counterparts. This extended conformation prevents these ligands 
from binding in the narrow active sites of MOR and DOR, likely contributing to their antagonist 
character. This extended pose also forces the ligands to sit higher in the opioid binding pocket, 
preventing the Tyr
1
 of the ligand from making favorable electrostatic interactions with the 
receptor. Most tight binding opioid peptide ligands form a salt bridge between the N-terminus of 
the peptide and a conserved Asp residue (Asp
147
 in MOR and Asp
145
 in DOR) deep in the opioid 
binding pocket. This higher binding pose also prevents a water mediated H-bond from forming 
between the hydroxyl group of Tyr
1
 of the ligand and a conserved His residue (His
297
 in MOR 
and His
278
 in DOR). This lack of electrostatic interactions likely contributes to the lower 
affinities for MOR and DOR seen in this series as compared to their cyclic counterparts. 
 Two compounds stand out in the DThr
2
 linear pentapeptide series: VRP-35 and JPAM7. 
Both of these compounds display appreciable agonism, VRP-35 at MOR and JPAM7 at DOR. 
Preliminary modeling studies suggest that this is because both of these ligands assume a more 
compact shape than the other ligands in this series, VRP-35 because the Aci
3
 kinks the peptide 
backbone of the ligand and JPAM7 because the Hfe
3
 is flexible enough to allow the ligand to 
fold in on itself. As VRP-35 displays the desired efficacy profile, it was modified with a Dmt
1
 to 
improve its binding profile. The resulting ligand, HVW-1, displays the desired binding profile, 
but the addition of two methyl group abolished all agonist activity at MOR. This is in line with a 
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trend observed in the cyclic mixed efficacy ligands where the addition of two methyl groups 




 in MOR, reducing efficacy. On the 
surface this observation appears to be at odds with previous reports of additional steric bulk 
conferring agonist character to TIPP analogues [33, 34]. However, the rationale for increased 
hydrophobic bulk lending agonist character to TIPP analogues rests on the idea that increased 
hydrophobicity in the first position allows the ligand to undergo so-called “hydrophobic 
collapse,” decreasing the overall size of the ligand and allowing it to fit into the narrower active 
site conformation. In our case, the added bulk in the first position does not significantly decrease 
the overall size of the molecule; in fact it increases the steric bulk at the N-terminus and 
consequently does not confer agonist character. 
 Fortunately, the converse is also true: reducing steric bulk at the N-terminus of the 
molecule rescues agonist activity. This is illustrated by the ligand pair JPAM12 and HVW-5, 
where a DSer
2
 is substituted for a DThr
2
. JPAM12 displays nanomolar binding, largely due to 
the Dmt
1





) we are able to rescue MOR efficacy. However, this effect is limited to MOR and HVW-5 
also displays DOR agonism. 
 While we did not generate a mixed efficacy MOR agonist/DOR antagonist ligand in our 
linear pentapeptide series, we have made several observations that will help direct future SAR 
efforts in this series. When comparing this series of ligands to the cyclic tetrapeptides described 
in Chapter 2.3 it becomes clear that making direct translations from cyclic to linear ligands did 
not achieve the desired result. By linearizing the peptides we lose the conformational restriction 
which gives our cyclic ligands their compact shape and allows them to selectively reduce DOR 
agonism. We are able to mimic this somewhat by introducing conformational restriction, as with 
VRP-35, or extreme flexibility, as with JPAM7, into the aromatic residue in the third position 
and reducing steric bulk in the second position, as with HVW-5. The next logical step would be 
to make a series of analogues which contain DSer
2
 with some conformational restriction in an 
attempt to selectively rescue MOR agonist activity. 
 For the hexapeptide series based on the Roques compounds we sought to add steric bulk 
in the fourth position to selectively reduce DOR agonism as we saw with the tetra- and 
pentapeptides described in Chapter 2. The only difference in sequence between this series and 
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the pentapeptide series described above is a Gly
3
 residue. While this may seem small, the added 
flexibility from a glycine is enough to confer full agonism at both MOR and DOR, where most 
ligands in the pentapeptide series were MOR and DOR antagonists. Given this extra flexibility it 
is unsurprising that the extra hydrophobic bulk in the fourth position was unable to reduce DOR 
efficacy – the ligand is not constrained enough to form a steric clash in the active site. JPAM16 
stands out in this series as it is the only compound to selectively display MOR agonism. 
Unfortunately, JPAM16 also displays poor binding to MOR and DOR. The incorporation of a 
Dmt
1
 (JPAM17) increased binding at MOR and DOR as expected, but also abolished all agonist 
activity. Future directions will include the DSer
2
 analogue of JPAM17, to see if the decreased 
bulk of a DSer, relative to a DThr, will selectively rescue MOR agonist activity, resulting in a 
potent MOR agonist/DOR antagonist ligand. 
While we did not achieve our desired profile of MOR agonist/DOR antagonist, a potent 
MOR agonist/DOR agonist is also a desirable profile [4, 14, 29]. We have therefore appended a 
C-terminal glucoserine to our most promising MOR agonist/DOR agonist compound, VRP-39. 
The resulting ligand, HVW-2, retains low nanomolar binding to MOR and DOR, with selectivity 
relative to KOR, and displays MOR and DOR agonism. This ligand will be carried forward into 
animal studies to compare how a MOR agonist/DOR agonist ligand compares to a MOR 
agonist/DOR antagonist compound in tolerance, dependence, and self-administration assays. 
 
3.5 Materials and Methods 
3.5.1 Materials 
All reagents and solvents were purchased from commercial sources and used without further 
purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. Louis, 
MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue culture 
reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). Radioactive 
compounds were purchased from Perkin-Elmer (Waltham, MA, USA). Peptide synthesis 
reagents, amino acids, and Rink resin were purchased from Advanced Chem Tech (Louisville, 
KY, USA). Wang resins were purchased from Nova Biochem, EMD (Gibbstown, NJ, USA). 
MMP-2200 was a kind gift from Dr. Robin Polt. Fmoc-Ser (b-GlcAc4)-OH (the glycosylated 
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serine building block) was synthesized by Larisa Yeomans accordingly to previously published 
protocols [35]. 
3.5.2 Solid-Phase Peptide Synthesis on CS Bio 
Peptides were synthesized using standard solid phase Fmoc 
(fluorenylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Synthesizer (CS Bio 
Company, Menlo Park, CA, USA), using previously described protocols. [36] C-terminal amide 
peptides were synthesized using Rink resin, C-terminal acid peptides were synthesized using 
Fmoc-Wang resin preloaded with the C-terminal amino acid. A 20% solution of piperidine in N-
methyl-2-pyrrolidone (NMP) was used to remove the first Fmoc protecting group before 
synthesis and again to remove the Fmoc-protecting group after each coupling cycle. Coupling 
was performed using a four-fold excess of amino acid and a solution of 0.4 M 
hydroxybenzotriazole (HOBt) and O-benzotriazole-N,N,N',N'-tetramethyl-uroniumhexafluoro- 
phosphate (HBTU) in dimethylformamide (DMF), in the presence of diisopropylethylamine 
(DIEA). After the synthesis was complete, the resin was washed with NMP, then with 
dichloromethane, and dried under vacuum. The peptides were cleaved from the resin and side-
chain-protecting groups removed by treatment at room temperature for 2 h with a cleavage 
cocktail consisting of 9.5 mL trifluoroacetic (TFA) acidand 0.5 mL water. The solution was 
concentrated in vacuo, and peptides were precipitated using cold diethylether. The filtered crude 
material was then purified using a Waters semipreparative HPLC (Waters Corporation, Milford, 
MA, USA) with a Vydac Protein and Peptide C18 column, using a linear gradient 10% Solvent B 
(0.1% TFA acid in acetonitrile) in Solvent A (0.1% TFA acid in water) to 60% Solvent B in 
Solvent A, at a rate of 1% per minute. The identity all peptides were determined ESI-MS 
performed on an Agilent Technologies LC/MS system using a 1200 Series LC and 6130 
Quadrupole LC/MS (Agilent Technologies, Santa Clara, CA, USA) in positive mode with 50–
100 µL injection volume and a linear gradient of 0% Solvent D (0.02% TFA and 0.1% acetic 
acid (AcOH) in acetonitrile) in Solvent C (0.02% TFA and 0.1% AcOH in water) to 60% Solvent 
D in Solvent C in 15 min. The purity of all peptides was determined using a Waters Alliance 
2690 Analytical HPLC (Waters Corporation, Milford, MA, USA) and Vydac Protein and Peptide 
C18 reverse phase column, using a linear gradient of 0–70% Solvent B in Solvent A at a rate of 
1% per minute. Linear peptides were purified to ≥ 95% purity by UV absorbance at 230 nm. 
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3.5.3 Solid Phase Peptide Synthesis on Microwave 
Peptides were synthesized using solid phase Fmoc (fluorenylmethyloxycarbonyl) 
chemistry as described above on a Discover S-Class CEM microwave using Synergy software. 
Deprotection of the first Fmoc protecting group was performed using a 20% solution (v/v) of 
piperidine in N-methyl-2-pyrrolidone (NMP) with “Fmoc deprotection” program (power: 20 W, 
Time: 1:30 min, Temperature: 75˚C, Δ Temperature: 0˚C) on the microwave synthesizer 
followed by three washes of NMP. Double coupling was then preformed using a 4.0x 
equivalence of the amino acids, 0.4M O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium 
hexafluorophosphate (HATU) and 1-hydroxy-7-azabenzotriazole (HOAt) in dimethylformamide 
(DMF) (2.5mL), 0.125M diisopropylethylamine (DIEA) (1mL), NMP (2.5mL),  and the 
“Coupling” program (power: 20W, Time: 5:00 min, Temperature: 75˚C, Δ Temperature: 5˚C) on 
the microwave synthesizer. After each double coupling the resin was washed with three times 
with NMP. After the final “Fmoc deprotection” the resin was washed three times with NMP then 
three times with methylene chloride (DCM) and dried under vacuum. Cleavage, deprotection, 
and purification were then performed as described in Section 3.4.3. 
3.5.4 Cell Lines and Membrane Preparations  
C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid 
receptor [37] and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) 
opioid receptor [38] were used for all in vitro assays. Cells were grown to confluence at 37ºC in 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with 
ice cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). 
Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 
150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200xg for 3 min. The 
cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized with a 
Tissue Tearor (Biospec Products, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The 
homogenate was centrifuged at 20,000xg for 20 min at 4 C, and the pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The 
final pellet was resuspended in 50mM Tris-HCl and frozen in aliquots at -80ºC. Protein 
concentration was determined via Bradford assay using bovine serum albumin as the standard. 
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3.5.5 Radioligand Binding Assays 
Opioid ligand-binding assays were performed using competitive displacement of 0.2 nM 
[
3
H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane preparations 
containing opioid receptors. The assay mixture, containing membrane suspension (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine, and various concentrations 
of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. 
The samples were rapidly filtered through Whatman GF/C filters  using a Brandel harvester 
(Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl buffer. The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, 
Waltham MA, USA). Nonspecific binding was determined using 10 μM naloxone. Ki values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
data using GraphPad Prism version 5.01 for Windows. The results presented are the mean ± 
standard error from at least three separate assays performed in duplicate. 
3.5.6 Stimulation of [
35
S]GTPγS Binding  
Agonist stimulation of [
35
S] guanosine 5'-O-[gamma-thio]triphosphate ([
35
S]GTPγS, 
1250 Ci, 46.2TBq/mmol) binding was measured as described previously [39].  Briefly, 
membranes (10-20 μg of protein/tube) were incubated 1 h at room temperature in GTPγS buffer 
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [
35
S]GTPγS, 30 μM 
guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation 
of [
35





enkephalin  (DAMGO) at MOR, D-Pen
2,5
- enkephalin (DPDPE) at DOR, or U69,593 at KOR. 
The reaction was terminated by rapidly filtering through GF/C filters and washing ten times with 
GTPγS buffer, and retained radioactivity was measured as described above.  The results 
presented are the mean ± standard error from at least three separate assays performed in 






3.5.7 Receptor Modeling  
The homology modeling of opioid receptors in complexes with peptide ligands was 
performed as previously described. [8, 22, 40] The procedure included the following steps: 1) 
residue substitution in corresponding structural template(s); 2) rigid body helix movement to 
reproduce structural rearrangement during receptor activation observed in crystal structures of 
rhodopsin and adrenergic receptor; [41] 3) peptide ligand docking in accordance with 
mutagenesis-derived constraints; and 4) refinement of receptor-ligand complex using distance 
geometry and energy minimization with CHARMm. The validity of this modeling procedure has 
been assessed in blind prediction experiments of structural modeling of MOR, [8, 22] A2a-
adenosine receptor, [42] CXCR4, and D3 dopamine receptor [40] performed before the release 
of the corresponding crystal structures. The following comparison with experimental structures 
showed relatively high accuracy of our homology models: rmsd were between 1.5 and 2.5 Ǻ for 
seven transmembrane helices [40, 42]. A comparison of our previously developed opioid 
receptor models [8, 22, 28, 43] and recently released crystal structures of the mouse MOR [44] 
and the human KOR  [45] demonstrated the high reliability in prediction of ligand-receptor 
interactions in the more conserved “message” region located deeply in the ligand binding pocket, 
and less precise modeling in the “address” region of flexible extracellular loops which are 
responsible for ligand selectivity. Despite some inaccuracies, the previous models suggested the 









side chains, respectively, and aromatic interactions between pentapeptide Phe
4
 side chain and 
residues from the extracellular loop 2. [8, 9, 28, 43] Here we used X-ray structures of MOR 
(PDB ID: 4dkl) and KOR (PDB ID: 4djh) to refine the models of MOR and KOR complexes 
with antagonists, especially in the variable loop regions, and to develop the homology model of 
antagonist-bound conformation of the human DOR (UniProt ID: P41143, residues 46-333). 
Further, we used the crystal structure of the human KOR (PDB ID: 4djh) together with our 
previous models of active conformations of opioid receptors [8, 22] for modeling of the active 
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4.1 Introduction 
As discussed in Chapters 1, 2, and 3, it has been demonstrated that the co-administration 
of a mu opioid receptor (MOR) agonist with either a delta opioid receptor (DOR) agonist or 
antagonist changes the in vivo pharmacology observed, limiting the development of tolerance to 
and dependence on MOR agonists, potentiating antinociception, and in some cases reducing self-
administration. However, the molecular underpinnings of this phenomenon are not well 
understood. We know that opioid receptors, like all GPCRs, are surface expressed receptors that 
bind extracellular ligands and couple to intracellular downstream signaling partners. We also 
know that upon exposure to agonist, opioid receptors are first desensitized, then internalized into 
intracellular vesicles, and are then either recycled to the plasma membrane as re-sensitized 
receptors or degraded. This cycle of agonist binding, desensitization and internalization has been 
linked to development of tolerance [1-6].  As described in Chapters 1.1 and 1.3, there is a 
growing body of literature that suggests that many GPCRs oligomerize both in vitro and in vivo 
[7-9]. It has been proposed that oligomers, usually dimers, are the native functional state of 
opioid receptors and homo- and heterodimerization can be used to explain the wide range of 
functional pharmacology seen in vivo and under various conditions in vitro [10-16].  
Several studies have suggested that MOR and DOR heterodimerize to form unique ligand 
binding and G protein activating units [9, 17-19]. This theory has been used to explain the effect 
that DOR and DOR ligands have on the potency and efficacy of MOR agonists, as well as the 
development of negative side effects and neurochemical adaptations to MOR agonists [20-25] 
and proposes that the native receptor state for MOR and DOR is either a homo- or heterodimer. 
This theory has gained support as MOR and DOR have been shown to co-localize in the dorsal
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 root ganglion [26-28], a region of the brain associated with pain signaling. However, previous 
work in the GPCR field has shown that some Class A GPCRs are able to function as monomers 
and that oligomerization is not necessary for normal binding and signaling in all GPCR systems 
[29-34]. An exploration of the viability of monomeric MOR can be found in Appendix B and is 
discussed in reference [35]. These data raise questions about the necessity of oligomerization for 
opioid function and the role that oligomerization may play in vivo. 
At the present time researchers are deeply divided on the issue of functional opioid 
receptor oligomerization and whether or not it is necessary for the basic activity of the opioid 
receptors in vivo. Until recently, experiments exploring the interaction of various membrane 
bound receptors, such as the opioid receptors, were limited to ensemble measurements over a 
large population of cells (for a review of methods used see the following paper [9]). This allowed 
for generalizations about trends in the binding or efficacy of ligands, changes in the development 
of various conditions or biomarkers, or association through various intermediates, but did not 
speak to direct interactions between two or more receptors; measuring single molecule binding 
events and tracking individual receptors was below the detection limit of most techniques. 
However, with the correct tools, the trafficking and localization of receptors can now be 
monitored through fluorescence microscopy. In this chapter I will describe the design of probes 
and live cell platforms with which to explore the co-localization and trafficking of MOR and 
DOR in a single cell. With these tools I will explore how DOR and DOR ligands affect MOR 
trafficking and discuss what this means for the MOR/DOR effects which have been described in 
previous chapters.  
4.2 Fluorescent Peptide Probes 
4.2.1 Selective Fluorescent Opioid Ligand Design and in vitro Pharmacological Testing 
In order to explore the function and trafficking of native opioid receptors using 
fluorescence microscopy we must first design selective, fluorescent ligands to use as probes. To 
develop these probes we started with highly selective MOR and DOR ligands and added either a 
Cys or Lys residue as a handle for conjugation with the fluorophores through a maleimide or 
NHS ester linkage, respectively. Using literature precedent [36] and our models [25, 37-44], we 
have determined that, generally speaking, the C-terminus of opioid peptides is the best place to 
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add large hydrophobic, highly conjugated substituents, such as fluorophores, without drastically 
altering the binding or efficacy of the ligand. As will be described later, labeling with 
fluorophores often results in compounds that are slightly less potent at the targeted receptor and a 
loss of selectivity relative to the parent compound. By examining our homology models we 
determined that the loss in potency is likely due to added steric bulk which hinders binding to the 
target receptor and that the loss of selectivity is probably caused by non-specific hydrophobic 
interactions between the fluorophore and the extracellular loops of the off target receptors. 
Consequently, the selection of the correct fluorophore is important. We initially began with the 
Alexafluor series of dyes, as they are fairly soluble in aqueous solutions, come in a wide variety 
of excitation/emission spectra, and have been used in a literature precedent with minimal loss of 
affinity and selectivity [36]. Unfortunately, this series of dyes was not bright enough for our 
purposes and was also unstable under our visualization conditions and rapidly photobleached, 
making time course studies unfeasible. We subsequently switched to the Cyanine dyes, Cy3 and 
Cy5, as they have convenient excitation/emission spectra, are cost-effective, have high quantum 
yields, and are photo-stable under our purification, assay, and visualization conditions. 
Based on literature 
precedent [36], I have 
developed a selective, peptidic 
MOR ligand labeled with the 






(Figure 4.1), using as a 
scaffold the known MOR 
agonist [Lys
7
] dermorphin, an 
opioid peptide extracted from 
frog skin [45].  The addition 
of a C-terminal Cys to [Lys
7
] 
dermorphin left the MOR affinity and efficacy
5
 relatively unchanged, but significantly reduced 




] dermorphin, relative to DOR. We then 
                                                 
5
 In this work “agonism” and “efficacy” refer to the ability of compounds to stimulate G protein turnover in the 
GTPγS assay. Details can be found in Section  4.5.10.  




) Dermorphin –The core 
structure for dermorphin is shown in black, the C-terminal Cys extension 
shown in blue, and the Cy3 fluorophore shown in red. 
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conjugated various fluorophores to this modified dermorphin; the binding affinities and 





]dermorphin for our microscopy studies not only because it displays a desirable 
binding and efficacy profile, but also because the Cy dyes nicely fit our needs. As described 
above the Cy dyes are cost effective, have relatively high quantum yields, are photostable under 
our purification and assay conditions, were compatible with our microscopy facilities, and the 
resulting conjugated ligands are relatively straightforward to purify as compared to other 
fluorescently labeled derivatives.  
We have also generated a selective, fluorescent, DOR antagonist, Dmt-Tic-Lys(Cy5)-OH 
(Figure 4.2), based on a previously reported selective DOR antagonist scaffold [46, 47]. (The 
selective fluorescent DOR antagonist Dmt-Tic-Lys(Cy5)-OH was developed and characterized 
by Dr. Mary F. Divin). Binding and efficacy data can be found in Table 4.2. Taken together, we 
have a MOR agonist/DOR antagonist pair that can be used with fluorescence microscopy to 
monitor the location of MOR and DOR in live cells.  
We next sought to fill out our tool box in order to more thoroughly explore the 
MOR/DOR receptor/receptor interactions. While we are most interested in how a MOR agonist 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO at 10µM . All values are expressed as mean ± SEM of three separate assays performed 
in duplicate. nd = not determined 
 
 
Table 4.1: In Vitro Binding and Efficacy Data for Selective Fluorescent MOR Agonists 
Sequence









[Lys7, Cys8] Dermorphin Tyr-DAla-Phe-Gly-
AF488 Tyr-Pro-Lys-Cys(AF488)-NH2









1.6±0.5 383±140 nd nd
104±4
95±3131±03.8± 1.8








and a DOR antagonist affect the trafficking, 
internalization, and recycling of opioid receptors, in 
order to fully explore the functional crosstalk between 
MOR and DOR a full complement of MOR and DOR 
ligands should be used. The state of the receptor 
(agonist bound vs. antagonist bound) affects the overall 
conformation of the receptor, may influence its ability 
to dimerize, and the receptors’ association with 
downstream signaling partners and cellular scaffolding. 
This, in turn, may affect the trafficking of receptors or 
the apparent potency or efficacy of a given ligand. By 
monitoring the localization of MOR and DOR under 
various drug conditions we may be able to draw 
inferences as the mechanism(s) of DOR and DOR 
ligands’ influence on MOR. 
Our efforts to generate a complete toolbox of MOR and DOR ligands have utilized 
various literature precedents to preserve or alter the selectivity and efficacy of reported ligands. 
Unfortunately, we have had a major problem with the selectivity of the ligands, especially after 
modification for and labeling with a fluorophore. Our various approaches have met with limited 
success; a more detailed description of our attempts to generate a selective, fluorescent MOR 
antagonist and DOR agonist can be found in Appendix A.   
Sequence
MOR DOR KOR % Ke (nM)
Dmt-Tic-Lys-OH Dmt-Tic-Lys-OH >1,000 1.2±0.6 >10,000 dns 11.3±5.9
Dmt-Tic-Lys(Cy3)-OH Dmt-Tic-Lys(Cy3)-OH >1,000 4.6±1.2 >1,000 dns 8.5±2.3
Dmt-Tic-Lys(Cy5)-OH Dmt-Tic-Lys(Cy5)-OH >1,000 4.7±0.7 >1,000 dns 13.4±5.4
Binding (nM) DOR Efficacy
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. The [
35
S]GTPγS assay was used to determine agonist potency 
(EC50, nM) and antagonist potency (Ke, nM) vs. known DOR agonist SNC80. All values are expressed as mean ± 
SEM of three separate assays performed in duplicate. dns = does not stimulate. 
 
 
Table 4.2: In Vitro Binding and Efficacy Data for Selective Fluorescent DOR Antagonists 
Figure 4.2: Structure of Dmt-Tic-
Lys(Cy5)-OH –The core structure for 
Dmt-Tic-Lys is shown in black, and the 
Cy5 fluorophore shown in green. 
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4.2.2 Fluorescent Ligand Viability as Probes for Confocal Microscopy in Live Cells 
 We have achieved some success in designing potent, selective fluorescent opioid ligands 
for MOR and DOR for use with confocal microscopy. We have in hand the two most interesting 










] dermorphin potently and selectively binds to MOR and 
stimulates G protein turnover in membrane preparations, displaying full agonist character. When 




] dermorphin is initially 
plasma membrane bound (Figure 4.3C) and the Cy3 signal internalizes over time to form 
intracellular puncta (Figure 4.4C). This signal pattern is consistent with initial binding of ligand 
to plasma membrane bound MOR and subsequent internalization of agonist bound MOR to 
intracellular vesicles. We have also demonstrated that this signal is blocked by the co-
administration of 10 µM naloxone, indicating that this signal is an opioid specific one (data not 




(Cy3)] dermorphin is administered 





] dermorphin as a MOR specific probe in live cell systems expressing both MOR and 
DOR. 
When characterizing the DOR antagonist Dmt-Tic-Lys(Cy5)-OH in membrane 
preparations, we found that it potently and selectively bound to DOR, without stimulating the 
receptor. In live cells expressing DOR, fluorescence microscopy studies showed that Dmt-Tic-
Lys(Cy5)-OH localized to the plasma membrane (Figure 4.5). The Cy5 signal from Dmt-Tic-
Lys(Cy5)-OH was monitored over the course of 60 minutes at 37˚C and remained on the plasma 
membrane over this time period (data not shown). This is consistent with binding to plasma 
membrane bound DOR; the signal does not move over time as antagonist bound opioid receptors 
remain on the surface of the cell. Again, we have demonstrated that this signal is blocked by the 
co-administration of 10 µM naloxone, indicating that this signal is an opioid specific one (data 
not shown) and that no signal is recorded when Dmt-Tic-Lys(Cy5)-OH is administered to cells 
which express only MOR (data not shown). This demonstrates the viability of Dmt-Tic-









] Dermorphin Internalized –  C6 cells stably expressing MOR treated with 5 




(Cy3)] dermorphin for 20 mins at 37C then washed an imaged at 
37C (total drug exposure approximately 25 mins). (A) Hoescht nuclear stain (cyan) (B) Wheat germ agglutinin 




] dermorphin (red). We can 





] Dermorphin on the Plasma Membrane -   C6 cells stably expressing MOR 




] dermorphin for 10 mins on ice then washed 
an imaged at room temperature (total drug exposure approximately 15 mins). (A) Hoescht nuclear stain (cyan) 





] dermorphin (red). A clear Cy3 signal that co-localizes with the plasma membrane stain is shown, though 
intracellular puncta are already starting to form. 
A B C 
C A B 
Figure 4.5: Dmt-Tic-Lys(Cy5)-OH on the Plasma Membrane –  C6 cells stably expressing DOR treated with 
5 ug/mL cellular stains and 100 nM Dmt-Tic-Lys(Cy5)-OH for 20 mins at 37C then washed an imaged at 37C 
(A) Hoescht nuclear stain (cyan) (B) Wheat germ agglutinin AlexaFluor 488 plasma membrane stain (yellow) 




4.3 Live Cell Platforms to Monitor the Trafficking of MOR and DOR 
The trafficking and expression patterns of opioid receptors are closely associated with 
their sensitivity and function. In fact, the development of tolerance to MOR agonists has been 
linked to a decrease in the number of active MORs available on the plasma membranes [48]. 
This decrease may be due to internalization of receptors after agonist treatment, which reduces 
the number of surface expressed receptors [1, 2]. Conversely, tolerance to MOR agonists has 
also been linked to a lack of internalization of MOR; it has also been proposed that MOR 
agonists that do not produce robust internalization, such as morphine, produce tolerance and 
dependence because internalization is necessary for re-sensitization of receptors and their 
subsequent trafficking to the cell surface [4-6, 49, 50]. 
In order to explore the effects of DOR and DOR antagonists on MOR trafficking we have 
used our selective, fluorescent, opioid ligands to monitor the trafficking and expression patterns 
of opioid receptors in live cell systems using fluorescence confocal microscopy. We have 
demonstrated that we can visualize both MOR and DOR in live cells expressing a single opioid 
receptor, monitor the trafficking (if any) in these cells, and that the dose of drug used is selective 
for the target receptor and does not interfere with imaging via fluoresence microscopy (see 
Chapter 4.2). However, in order to examine the trafficking of MOR and DOR, and how various 
drug combinations affect that trafficking, a cell line that expresses both MOR and DOR needs to 
be generated.  
Plasmids encoding the untagged human and rat MOR and human and rat DOR (hMOR, 
rMOR, hDOR and rDOR respectively) with orthogonal antibiotic resistances have been 
generated. Both C6 and HEK cells were stably transfected with hMOR and cell lines expressing 
hMOR at varying receptor expression levels were isolated and characterized. Attempts were then 
made to co-transfect these cell lines with hDOR. However no viable clones were isolated – cells 
either down-regulated receptor expression such that they were viable in selective media but did 
not express measurable levels of receptor or simply died in selective media. Attempts were then 
made to transfect our existing C6 cells expressing rMOR with either rDOR or hDOR, however all 
of these attempts failed as well with cells either surviving selection but not expressing receptor 
or dying upon exposure to selective antibiotic. The reverse was then tried and C6rDOR cells of 
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varying expression levels were transfected with hMOR or rMOR; all of these attempts also failed 
to produce viable clones that expressed both opioid receptors.  
We next attempted to image binding of our fluorescent ligands to SH SY5Y cells; SHSY 
5Y is a human derived neuroblastomal cell line which endogenously expresses both hMOR and 
hDOR. Unfortunately, expression levels were too low to see binding of fluorescent ligand using 
fluorescence confocal microscopy; experiments in SHSY 5Y cells were not pursued further. 
A literature search yielded reports from the Devi lab [17] and the Whistler lab [51, 52] of 
cells that expressed low levels of both MOR and DOR and a report of CHO cells over-expressing 
both MOR and DOR from the Wang lab [53]. The Wang lab (University of Maryland) was 
contacted and a sample was obtained. Unfortunately, in our hands the Bmax for total opioid 
receptor expression was approximately one third of that reported by the Wang lab and 
subsequent passages of these cells continued to lose receptor expression. By passage 5 these 
MOR/DOR CHO cells were expressing MOR and DOR at levels similar to SH SY5Y cells. A 
preliminary confocal microscopy experiment was attempted, but fluorescent ligand binding was 
below the detection limit and these cells were not pursued further for fluorescence microscopy 
use. The cells described by the Whistler lab were not thoroughly described in any publications 
and no further information on receptor expression levels or viability could be found. 
An informal communication with the Devi lab, which works extensively with opioid 
receptor pharmacology, indicated that they have generated CHO cells that express low levels of 
both MOR and DOR [17], but that these cells lose receptor expression over time, in a manner 
similar to that which I found in my HEK and C6 cell lines. Informal communications with the 
Akil, Wats, and Uhler labs, which were responsible for the initial cloning of the opioid receptors, 
yielded more information about early expression of the opioid receptors. Anecdotally, there is 
significant toxicity associated with the over-expression of opioid receptors; this goes a long way 
toward explaining why there are so few reports of cells stably over-expressing both MOR and 
DOR despite the interest in mixed efficacy ligands and MOR/DOR receptor-receptor 
interactions. This may also explain why the few viable clones which have been reported seem to 
down-regulate receptor expression over time and why few regions of the brain seem to co-
express MOR and DOR in the same cell.  
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To side step the problem of stable co-expression of MOR and DOR we turned to transient 
transfection with fluorescently tagged receptors. We started with C6 cells stably over-expressing 
rMOR and transfected in DOR. As the transfection efficiency of C6 cells is relatively low we 
used cyan fluorescent protein (CFP) tagged hDOR (CDOR) to mark cells that express both the 
stable and transiently expressed receptors. We performed controls with CDOR to ensure that it 
behaved in a manner consistent with its unlabeled counterpart, DOR, when transiently expressed. 
C6 wild type cells transiently expressing CDOR showed that CDOR was held primarily in 
internal stores, consistent with the expression pattern of unlabeled DOR [54, 55].  There was, 
however, enough surface expression of CDOR to bind our DOR selective antagonist Dmt-Tic-
Lys(Cy5)-OH. The Cy5 signal only occurred on the plasma membrane of cells that expressed 
CDOR and remained there over time, consistent with the fact that opioid antagonists do not 
cause receptors to internalize (Figure 4.6).  
 Having confirmed that CDOR is expressed, binds antagonist, and remains surface 
expressed in a manner consistent with its unlabeled counterpart when transiently expressed in 
wild type cells, we next transiently transfected C6rMOR with CDOR to determine if any 
difference in trafficking is noted when both receptors are present. We first examined the 




] dermorphin independently to 
determine if the presence of both MOR and DOR in the same cells was enough to alter 
trafficking. Live C6rMOR cells transiently expressing CDOR bound the delta antagonist Dmt-
Tic-Lys(Cy5)-OH on the plasma membrane. Cells were imaged every 5 minutes for 30 minutes; 
the ligand remained plasma membrane bound over time, indicating that the presence of MOR 
does not alter the trafficking of antagonist bound DOR (Figure 4.7). Those C6rMOR cells that 
did not express CDOR did not bind Dmt-Tic-Lys(Cy5)-OH. We next treated the live C6rMOR 




] dermorphin. Cells that expressed both 
MOR and CDOR bound and internalized MOR agonist in a manner similar to cells expressing 
only rMOR (Figure 4.8). Taken together, these experiments indicate that the presence of both 
MOR and DOR in the same cell does not alter the trafficking of MOR in the presence of a MOR 
agonist nor does it alter the trafficking of DOR in the presence of a DOR antagonist. This means 
that the effect of DOR on MOR agonist trafficking is not caused by the presence of the receptor 
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Figure 4.6: C6 Wild Type Cells Transiently Expressing CDOR Bind Dmt-Tic-Lys(Cy5)-OH – cells 
transiently expressing CDOR treated with 5 ug/mL cellular stains and 100 nM Dmt-Tic-Lys(Cy5)-OH for 50 
mins at 37C then washed an imaged at 37C (A) Wheat germ agglutinin AlexaFluor488 plasma membrane stain 
(yellow) (B) CFP (cyan) (C) Dmt-Tic-Lys(Cy5)-OH (green) the Cy5 and plasma membrane co-localize with 
each other. The CFP signal is mostly held in internal stores; those cells with the strongest CFP signal bind the 
most DOR drug and show the strongest Cy5 signal. 
A B C 
Figure 4.7: C6MOR Cells Transiently Expressing CDOR Bind Dmt-Tic-Lys(Cy5)-OH – cells stably 
expressing MOR and transiently expressing CDOR treated with 5 ug/mL cellular stains and 100 nM Dmt-Tic-
Lys(Cy5)-OH for 5 mins at RT then washed an imaged at RT after 30 mins (A) Wheat germ agglutinin 
AlexaFluor488 plasma membrane stain (yellow) (B) CFP (cyan) (C) DOR antagonist Dmt-Tic-Lys(Cy5)-OH 
(green). We can see that the Cy5 and plasma membrane co-localize with each other. The CFP signal is mostly 
held in internal stores; those cells with the strongest CFP signal bind the most DOR drug and show the strongest 
Cy5 signal. 





Dermorphin – cells stably expressing MOR and transiently expressing CDOR treated with 5 ug/mL cellular 




] dermorphin 5 mins at RT then washed an imaged at RT after 30 mins (A) 





] dermorphin (red). (C) Overlay of Cy3 and WGA488 signals. We can see that the Cy3 signal 
is internalized in all cells, regardless of the presence or absence of CDOR. 
A B C 
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We next explored the effect of pre-treatment with DOR antagonist on MOR trafficking in 
cells that expressed both receptors. C6rMOR cells transiently expressing CDOR were treated 
with the DOR antagonist Dmt-Tic-Lys(Cy5)-OH to ensure that all DOR binding sites were 





dermorphin, and DOR antagonist Dmt-Tic-Lys(Cy5)-OH. Live cells were then imaged, the 
ligand only bound to cells expressing CDOR and remained on the surface of cells expressing 
both MOR and CDOR over time.  




] dermorphin, was 
altered in cells that expressed both MOR and CDOR in the presence of DOR antagonist. Cells 
were pre-treated with Dmt-Tic-Lys(Cy5)-OH to occupy all DOR binding sites with a DOR 
A B C 
D E F 
Figure 4.9: C6MOR Cells Transiently Expressing CDOR Pretreated with Dmt-Tic-Lys(Cy5)-OH, then 




] Dermorphin – cells stably expressing MOR and 
transiently expressing CDOR treated with 5 ug/mL cellular stains and then pretreated with 100 nM Dmt-Tic-





dermorphin 5 mins at RT then washed an imaged at RT after 30 mins (A) Wheat germ agglutinin 488 plasma 




] dermorphin (red). (C) DOR 
antagonist Dmt-Tic-Lys(Cy5)-OH (green) (D) Overlay of AF488 and Cy3 signals (E)Overlay of AF488 and 
Cy5 signals (F)Overlay of Cy3 and Cy5 signals. We can see that the Cy3 signal is internalized more robustly in 
cells that express CDOR and that the CDOR remains on the surface of the cell over time. 
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and our DOR antagonist Dmt-Tic-Lys(Cy5)-OH. In cells that expressed both receptors, MOR 
internalized 1.66 ± 0.12 fold more robustly than in cells that expressed only MOR (n=6 images 
with 1-3 cells expressing both MOR and CDOR in each frame; Figure 4.9). It has been proposed 
that internalization of MOR is a key part of re-sensitization and leads to recycling of the sensitive 
receptor, increasing cell surface expression of functional opioid receptors [4-6, 49, 50]. I have 
observed that DOR antagonists increase MOR internalization. If increased internalization of 
MOR leads to increased recycling of MOR, this could explain how DOR antagonists reduce the 
development of tolerance, as reduced surface expression of active receptor is a cellular hallmark 
of tolerance [1-6]. 
The mechanism by which antagonist bound DOR increases MOR internalization and 
recycling upon exposure to MOR agonist is unclear. An explanation for these data involves the 
active and inactive receptor conformations and the G proteins they associate with. A simplified 
model of the association of GPCRs with G proteins and ligands states that agonists bind to the 
active conformation of the receptor and promote the association and turnover of G proteins while 
antagonists bind to the inactive conformation of the receptor and prevent the association of G 
proteins [56].  Given that MOR and DOR compete for the same pool of G proteins and other 
downstream signaling partners [57], increasing the amount of antagonist bound DOR would free 
G proteins to associate with MOR. This is particularly significant as DOR has a high basal 
signaling rate [58, 59], so that even in the absence of DOR agonist a measurable amount of G 
protein will be associated with DOR. By increasing the pool of available G protein, agonist 
bound MOR will be more able to associate with and turn over G proteins, increasing the apparent 
potency of MOR agonists and the rate at which receptors are marked for internalization and 
recycling. This may explain the ability of DOR antagonists to potentiate the potency of MOR 
agonists as well as the ability of DOR antagonists to slow the development of tolerance to MOR 
agonists. 
4.4 Conclusions 
 The studies discussed in this chapter were designed to explore the changes in trafficking 
of MOR and DOR in the presence of a MOR agonist and a DOR antagonist, as this is a drug 
combination that has been shown to reduce the development of tolerance to and dependence on 
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] dermorphin, and 
a selective fluorescent DOR antagonist, Dmt-Tic-Lys(Cy5)-OH, were designed and 
characterized. I have demonstrated these ligands behave as expected in live cells expressing only 
one opioid receptor and that they can be used to monitor the trafficking, or lack thereof, of both 
MOR and DOR. I have also developed a live cell platform stably expressing rMOR and 
transiently expressing hCDOR such that cells that express both receptors can be compared to 
cells that only express rMOR in the same frame and under exactly the same drug conditions. I 
have utilized these tools to explore how the trafficking of MOR is altered in the presence of 
CDOR and DOR antagonist. 
 I found that in the presence of DOR antagonist cells that expressed both MOR and 
CDOR, agonist bound MOR internalized more robustly than in cells that expressed only MOR. 
This effect was seen only in the presence of DOR antagonist; DOR itself had no effect on agonist 
induced MOR trafficking. Given these data, I hypothesize that DOR antagonists exert their 
effects on MOR agonist potency and tolerance in the following manner. Antagonist bound DOR 
encourages a receptor conformation which allows for the dissociation of G protein. As DOR has 
a high basal turnover rate [58, 59] and MOR and DOR share a pool of G proteins and other 
signaling partners [57] this allows for more robust stimulation, internalization, and recycling of 
MOR in the presence of a MOR agonist. Taken together, this increased trafficking allows for 
greater cell surface expression of functional opioid receptors [4-6, 49, 50], leading to improved 
MOR agonist potency and reduced development of tolerance to MOR agonists, features 
characteristic of the co-administration of MOR agonists with DOR antagonists [60-64]. 
 Future work will explore the different effects of multifunctional ligands and drug 
cocktails on the trafficking of MOR and DOR. This will necessitate the development of a cell 
line that co-expresses two labeled receptors, as a multifunctional ligand will, by definition, bind 
to both MOR and DOR and therefore will not distinguish between the two receptors. Fluorescent 
labeling of MOR and DOR will, however, allow us to distinguish each receptor and will also 
expand the range of experiments that can be performed (e.g. drug cocktails of MOR 
agonist/DOR antagonist, MOR agonist/DOR agonist, MOR partial agonist/DOR antagonist, 
MOR agonist/DOR inverse agonist, various biased agonists for MOR and DOR or mixed 
efficacy ligands displaying any of these profiles) without the need for the difficult process of 
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designing fluorescent ligands that meet the desired pharmacological profile. This can be 
accomplished by transfecting cells with CDOR and a yellow-fluorescent protein labeled MOR 
(YMOR), for which I have already constructed plasmids with orthogonal antibiotic resistance. 
Preliminary experiments have already been performed with YMOR and I have shown that it 
behaves in a manner similar to unlabeled MOR  in mammalian cells and that the YFP signal can 
be used to monitor the trafficking of MOR (in vitro mammalian cell data not shown and [35]). I 
have already generated stable cell lines that over-express YMOR. Transient transfection of these 
cells with CDOR will allow us to perform experiments similar to those described in Chapter 4.3, 
but with a wider range of drug cocktails and multifunctional ligands, further elucidating the 
effects of DOR ligands on MOR trafficking. 
 
4.5 Materials and Methods 
4.5.1 Materials 
All reagents and solvents were purchased from commercial sources and used without 
further purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. 
Louis, MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue 
culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). Restriction 
enzymes and other molecular biology tools were purchased from New England Biolabs (Ipswich 
MA). Radioactive compounds were purchased from Perkin-Elmer (Waltham, MA, USA). 
Peptide synthesis reagents, amino acids, and Rink resin were purchased from Advanced Chem 
Tech (Louisville, KY, USA). Wang resins were purchased from Nova Biochem, EMD 
(Gibbstown, NJ, USA). Cy3 and Cy5 mono-reactive dyes were purchased from GE Healthcare 
(Piscataway, NJ), Alexafluor dyes and Lipofectamine reagents were purchased from Invitrogen 
(Carlsbad, CA). Original plasmids encoding for CDOR and YMOR were a kind gift from Dr. 
Roger Sunahara (University of Michigan, Ann Arbor, USA). Plasmids encoding for unlabeled 
human MOR and DOR were purchased from cDNA.org (Rolla, MO, USA). cDNA coding for 
the rat mu opioid receptor (rMOR) and the rat delta opioid receptor (rDOR), both in pCMV6neo 
(ampicillin and neomycin resistance), were a kind gift from the Dr. Huda Akil (University of 
74 
 
Michigan, Ann Arbor, MI). All fluorescent microscopy images were taken at the Microscopy 
Image Analysis Laboratory (University of Michigan, Ann Arbor). 
4.5.2 Solid-Phase Peptide Synthesis  
Peptides were synthesized using standard solid phase Fmoc 
(fluorenylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Synthesizer (CS Bio 
Company, Menlo Park, CA, USA), using previously described protocols. [43] C-terminal amide 
peptides were synthesized using Rink resin. A 20% solution of piperidine in N-methyl-2-
pyrrolidone (NMP) was used to remove the first Fmoc protecting group before synthesis and 
again to remove the Fmoc-protecting group after each coupling cycle. Coupling was performed 
using a four-fold excess of amino acid and a solution of 0.4 M hydroxybenzotriazole (HOBt) and 
O-benzotriazole-N,N,N',N'-tetramethyl-uroniumhexafluoro-phosphate (HBTU) in 
dimethylformamide (DMF), in the presence of diisopropylethylamine (DIEA). After the 
synthesis was complete, the resin was washed with NMP, then with dichloromethane, and dried 
under vacuum. The peptides were cleaved from the resin and side-chain-protecting groups 
removed by treatment at room temperature for 2 h with a cleavage cocktail consisting of 9.5 mL 
trifluoroacetic (TFA) acid, 0.25 mL triisopropylsilane (TIS) and 0.25 mL water for peptides with 
thiol containing side chains. All other peptides were cleaved with a cocktail containing 9.5 mL 
TFA and 0.5 mL water. The solution was concentrated in vacuo, and peptides were precipitated 
using cold, fresh diethylether. The filtered crude material was then purified using a Waters 
semipreparative HPLC (Waters Corporation, Milford, MA, USA) with a Vydac Protein and 
Peptide C18 column, using a linear gradient 10% Solvent B (0.1% TFA acid in acetonitrile) in 
Solvent A (0.1% TFA acid in water) to 60% Solvent B in Solvent A, at a rate of 1% per minute. 
The identity all peptides were determined ESI-MS performed on an Agilent Technologies 
LC/MS system using a 1200 Series LC and 6130 Quadrupole LC/MS (Agilent Technologies, 
Santa Clara, CA, USA) in positive mode with 50–100 µL injection volume and a linear gradient 
of 0% Solvent D (0.02% TFA and 0.1% acetic acid (AcOH) in acetonitrile) in Solvent C (0.02% 
TFA and 0.1% AcOH in water) to 60% Solvent D in Solvent C in 15 min. The purity of all 
peptides was determined using a Waters Alliance 2690 Analytical HPLC (Waters Corporation, 
Milford, MA, USA) and Vydac Protein and Peptide C18 reverse phase column, using a linear 
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gradient of 0–70% Solvent B in Solvent A at a rate of 1% per minute. Linear peptides were 
purified to ≥ 95% purity by UV absorbance at 230 nm. 
4.5.3 Fluorescent Labeling 
The purified peptide was labeled with Cy3 or Cy5 maleimide or NHS ester (GE 
Healthcare) according to the manufacturer’s instructions using a ratio of 1.5:1 peptide to 
fluorophore. The labeled peptide was further purified via semi-preparative HPLC using a 5 
micron Vydac C18 column as described above. The potency and efficacy labeled ligands 
confirmed in radiolabeled [
3
H]DPN competition and [
35
S]GTPγS binding assays. 
4.5.4 Stable Cell Lines and Membrane Preparations  
C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid 
receptor [65] and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) 
opioid receptor [66] were used for all in vitro assays. Cells were grown to confluence at 37ºC in 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum (FBS) and 
5% penicillin/streptomycin. Membranes were prepared by washing confluent cells three times 
with ice cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 
7.4). Cells were detached from the plates by incubation in warm harvesting buffer (20 mM 
HEPES, 150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200xg for 3 
min. The cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized 
with a Tissue Tearor (Biospec Products, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The 
homogenate was centrifuged at 20,000xg for 20 min at 4 C, and the pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The 
final pellet was resuspended in 50mM Tris-HCl and frozen in aliquots at -80ºC. Protein 
concentration was determined via Bradford assay using bovine serum albumin as the standard. 
4.5.5 DNA Amplification and Purification 
cDNA coding for the rat mu opioid receptor (rMOR) and the rat delta opioid receptor 
(rDOR), both in pCMV6neo (ampicillin and neomycin resistance), were a kind gift from the Dr. 
Huda Akil (University of Michigan, Ann Arbor, MI). cDNA for human MOR and DOR (hMOR 





(ampicillin and geneticin resistance). cDNA encoding for the HA-Flag-His(10)-
eYFP-hMOR and HA-Flag-His(10)-eCFP-hDOR, both in pcDNA3.1
-
(ampicillin and geneticin 
resistance), were a kind gift from the Dr. Roger Sunahara (University of Michigan, Ann Arbor, 
MI). When stable co-transfection was desired, the gene of interest was clipped from its parent 





 (Invitrogen, Carlsbad,CA), with ampicillin and 
zeocin antibiotic resistance was prepared with the same restriction enzymes and treated with calf 
alkaline phosphatase (New England Biolabs, Ipswich, MA) according to the manufacturer’s 
protocol. The gene of interest and the acceptor vector were then ligated using T4 DNA ligase 
(New England Biolabs, Ipswich, MA) according to the manufacturer’s protocol.   
For amplification of DNA, XL10-Gold Ultracompetent E. coli (Agilent Technologies, 
Santa Clara, CA) were transformed according to the manufacturer’s protocol and plated on LB 
agarose plates containing 100 µg/mL ampicillin for selection and grown at 37˚C overnight. 
Transformed colonies were picked and grown in 10 mL liquid LB media with 100 µg/mL 
ampicillin for 8 hours at 37˚C with shaking at 225 rpm. 250 mL liquid LB with 100 µg/mL 
ampicillin  were then inoculated with 1-5 mL of the 8 hour culture and grown overnight hours at 
37˚C with shaking at 225 rpm. Cells were then pelleted via centrifugation at 5,000 x g for 15 
minutes and DNA was then purified using Qiagen MaxiPrep kits (Qiagen, Germantown, MD) 
according to the manufacturer’s protocol.  
Purified plasmids were digested with various restriction enzymes (HindIII, BglII, or 
XMaI) and run on a 1.2% (w/v) agarose gel with TAE buffer with 0.1% ethidium bromide (v/v) 
in 1X TAE at 80-100 V for 1.5 hours to determine the direction of insertion of the gene of 
interest; samples with the correct directionality were sent to the DNA sequencing Core 
(University of Michigan, Ann Arbor, MI) for complete sequencing to determine if the insertion 
of the gene of interest was correct. 
4.5.6 Transient Transfection of Mammalian Cells 
 For transient transfection, mammalian cells, either HEK or C6, were grown to between 
80 and 95 percent confluency in 6 cm dishes and transfected with 30 µL Lipofectamine 2000 
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(Invitrogen, Carlsbad, CA) and between 3 and 7 µg of purified DNA according to the 
manufacturer’s protocol. 
4.5.7 Stable Transfection of Mammalian Cells 
 Prior to transection, the minimum concentration needed to kill wild type HEK or C6 was 
determined for each antibiotic or combination of antibiotics, hereafter referred to as “selective 
media.” For stable transfection, mammalian cells, either HEK or C6, were grown to between 80 
and 95 percent confluency in 6 cm dishes and transfected with 30 µL Lipofectamine 2000 
(Invitrogen, Carlsbad, CA) and between 7 and 10 µg of purified DNA according to the 
manufacturer’s protocol. 24 hours post transfection cells were split with antibiotic free DMEM 
with 10% FBS at varying various concentrations (e.g. 1:5, 1:10, 1:20, etc) and incubated at 37˚C 
with 5% CO2. 48 hours post transfection selective DMEM with 10% FBS was added to the cells 
and cells were incubated at 37˚C with 5% CO2. Cells were grown at 37˚C with 5% CO2 and 
media was exchanged every two days as non-transfected cells died off. When individual colonies 
of transfected cells emerged they were removed from the plate with 0.05% Trypsin with EDTA. 
Each individual colony was re-plated in 48 well plates and grown to confluency in selective 
media. As each clone reached confluency they were re-plated in larger and larger vessels in 
selective media until there were sufficient cells for a membrane preparation. Membrane 
preparations of each clone were prepared as described in section 4.5.4. Saturation binding assays 
were then performed as described in section 4.5.9 on membrane preparations to determine Bmax. 
4.5.8 Radioligand Binding Assays 
Opioid ligand-binding assays were performed using competitive displacement of 0.2 nM 
[
3
H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane preparations 
containing opioid receptors. The assay mixture, containing membrane suspension (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine, and various concentrations 
of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. 
The samples were rapidly filtered through Whatman GF/C filters  using a Brandel harvester 
(Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl buffer. The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, 
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Waltham MA, USA). Nonspecific binding was determined using 10 μM naloxone. Ki values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
data using GraphPad Prism version 5.01 for Windows. The results presented are the mean ± 
standard error from at least three separate assays performed in duplicate. 
4.5.9 Saturation Radioligand Binding Assays – Determining Bmax 
Opioid ligand-binding assays were performed using [
3
H]diprenorphine (250 µCi, 
1.85TBq/mmol). The assay mixture, containing membrane suspension (5-10 μg protein/tube) in 
50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine ranging from 0 to 4 nM, and either water or 
25µM naloxone, was incubated at room temperature for 1 h to allow binding to reach 
equilibrium. The samples were rapidly filtered through Whatman GF/C filters using a Brandel 
harvester (Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl 
buffer. The radioactivity retained on dried filters was determined by liquid scintillation counting 
after saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-
Elmer, Waltham MA, USA). Counts for nonspecific binding (naloxone) were substracted from 
total counts (water). Saturation values were calculated using saturation regression analysis using 
GraphPad Prism version 5.01 for Windows. The results presented are the mean ± standard error 
from at least three separate assays performed in duplicate. 
4.5.10 Stimulation of [
35
S]GTPγS Binding  
Agonist stimulation of [
35
S] guanosine 5'-O-[gamma-thio]triphosphate ([
35
S]GTPγS, 
1250 Ci, 46.2TBq/mmol) binding was measured as described previously [67].  Briefly, 
membranes (10-20 μg of protein/tube) were incubated 1 h at room temperature in GTPγS buffer 
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [
35
S]GTPγS, 30 μM 
guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation 
of [
35





enkephalin  (DAMGO) at MOR, D-Pen
2,5
- enkephalin (DPDPE) at DOR, or U69,593 at KOR. 
The reaction was terminated by rapidly filtering through GF/C filters and washing ten times with 
GTPγS buffer, and retained radioactivity was measured as described above.  The results 
presented are the mean ± standard error from at least three separate assays performed in 
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duplicate; maximal stimulation was determined using nonlinear regression analysis with 
GraphPad Prism. 
4.5.11 Visualization of Live Cells Using Fluorescence Confocal Microscopy 
 Samples were imaged at ambient temperature unless otherwise specified using a 60 X 
water lens on an Olympus Fluo-View 500 laser scanning confocal microscope operating with 
FluoView FV500 TIEMPO software (Olympus Co, LTD, Melville, NY) at the Microscopy and 
Image Analysis Laboratory (University of Michigan, Biomedical Research Core Facility, Ann 
Arbor, MI). Samples were imaged using a four laser system includes 405 diode, multiline Argon, 
HeNe green and HeNe red and preprogramed filters. Invitrogen’s SpectraViewer (Invitrogen, 
Carlsbad, CA) was used to choose appropriate laser and filter settings as well as informing our 
choice of cellular stains.  Z stacks were 1 AU thick, set to either the 405 or 488 nm laser, 
whichever was in use at the time. Images were taken at 1024x1024 dpi resolution with Kalman 
line by line noise reduction over 4 to 8 scans. 
24 hours prior to visualization, cells were split into sterile borosilicate chambered 
coverglasses (Lab-Tek, Fisher Scientific, Pittsburgh PA) such that they were approximately 65 to 
85 percent confluent. All drug solutions for live cell sample imaging were diluted in serum and 
phenol red free DMEM – hereafter referred to as “media” – as fetal bovine serum (FBS) and 
phenol red auto-fluoresce in the Cy3 and Cy5 channels. Hoechst nuclear stain and Alexa Fluor 
conjugated wheat germ agglutinin plasma (WGA) membrane stains were acquired from 
Invitrogen (Carlsbad, CA) as lyophilized solids and 1mg/mL stock solutions were prepared in 
MilliQ  water (EMD Millipore, Billerica, MA) and stored at -20˚C. Live cells samples were 
stained using 1µg/mL solutions of the cellular stains media for imaging. Stock solutions of 
purified fluorescent ligands were prepared at 100 µM in DMSO and stored at -20˚C. Live cell 
samples were exposed to 100 nM concentrations of fluorescent drug in media for imaging. 
Unless otherwise specified, cells were first incubated with cellular stains in media for 10 
minutes at room temperature and then washed with media and imaged to obtain control images. 
Cells were then incubated with drug solutions for 5 minutes at room temperature, then washed 









All analyses were performed on still images taken from fluorescence microscopy studies 
and were analyzed using Image Pro Premier version 9.0.3 (MediaCybernetics, Rockville, MD, 
USA). Macros for the automation of defining cell boundaries were designed by Jeff Knipe at 
MediaCybernetics. These boundaries were defined by smoothing the signal from the plasma 
membrane stain and allowed for manual separation of neighboring cells. The intensity of Cy3 
signal within the cell boundaries was then measured. The Cy3 signal was divided over the area 
within each boundary to give an average intensity of Cy3 signal for each cell. The average 
intensity of signal in cells expressing both MOR and CDOR was then compared to the average 
intensity of signal for cells expressing only MOR in 6 separate images containing 1-3 cells that 
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5.1 Overview of the Problem 
 Opioid analgesics are some of the most clinically effective compounds for treating 
chronic and acute pain in use today. Most clinically relevant opioid analgesics are mu opioid 
receptor (MOR) agonists. Unfortunately, MOR agonist analgesics have significant drawbacks, 
including the development of tolerance and dependence; MOR agonists also display 
euphorigenic qualities. Together these features limit the clinical usefulness of opioid analgesics 
and contribute to the social problems associated with their illicit use [1].  
 It has been demonstrated that the co-administration of a MOR agonist with either a delta 
opioid receptor (DOR) antagonist [2-5] or agonist [6-8] mitigates the development of tolerance 
and dependence and may even reduce the addiction liability associated with opioid use [9]. This 
project has explored the development of mixed efficacy MOR/DOR ligands and the functional 
crosstalk between the mu and delta opioid receptors. 
5.2 Summary of Research 
5.2.1 Development of Mixed Efficacy MOR/DOR Ligands 
 In order to exploit the desirable pharmacological profile displayed by the co-
administration of a MOR agonist with either a DOR antagonist or agonist we sought to combine 
both functionalities into the same molecule. This approach is preferable to simply administering 
two selective ligands, as it eliminates potential problems associated with giving two separate 
chemical entities with possibly differing pharmacokinetic and metabolic profiles.  Two families 
of mixed efficacy peptides were developed, cyclic and linear, which are described below. 
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5.2.2 Cyclic Mixed Efficacy MOR/DOR Peptides 
 Two series of cyclic mixed efficacy MOR agonist/DOR antagonist peptides were 
generated: a series of pentapeptides based on a previously developed non-selective opioid 
agonist, MP-143 (MP compounds synthesized by Maggie Przydzial), and a series of 
tetrapeptides that improved upon a previously developed mixed efficacy ligand, KSK-102 (KSK 
compounds synthesized by Kate Sobczyk-Kojiro). Information from our previously described 
homology models of the active and inactive states of MOR, DOR, and the kappa opioid receptor 
(KOR) [10-16] was used to guide the development of these ligands. 
 Replacement of the Phe
4
 in the pentapeptide series drastically reduced KOR binding and 
efficacy. Docking studies showed that Phe
4
 of MP-143 is in close proximity to Tyr
219
 in the 
KOR active site and they likely form a favorable π-π stacking interaction. By replacing Phe
4
 of 
the ligand with an aliphatic residue problematic KOR agonist activity is removed while 
preserving MOR and DOR binding and efficacy.  
We next sought to reduce DOR efficacy, as we wanted to design a mixed efficacy MOR 
agonist/DOR antagonist. As the binding pocket for active DOR is narrower than the active MOR 
binding pocket we reasoned that increased steric bulk would selectively produce a steric clash in 
the DOR active site, thereby reducing DOR efficacy.  We explored several factors: the size of the 
cycle between the second and fifth bridging residues, the stereochemistry of the amino acid in 
the fifth position, and both carboxylic acid and carboxamide C-termini. This proved to be a 
successful strategy. We developed two promising mixed efficacy pentapeptides – LP-32 (LP 
compounds synthesized by Lauren Purington) and JPAM3 (SS) – demonstrating the validity of 
our homology models and making progress toward our goal of developing cyclic MOR 
agonist/DOR antagonist peptides. However, it is worth noting that in this series the reduction in 
DOR efficacy was not totally selective. In the instances where DOR efficacy was greatly reduced 
DOR binding and MOR efficacy were often negatively affected.  
The next stage in the development of cyclic mixed efficacy ligands was the exploration of 
our tetrapeptide scaffolds. This series contained only one hydrophobic residue within the 
cyclized portion of the molecule. In this series the size and flexibility of the residue in the third 
position and the size of the cyclization between the bridging second and fourth residues were 
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altered to exploit the difference in the MOR and DOR active sites. We sought to balance MOR 
and DOR binding and remove the residual DOR efficacy found in our lead peptides from the 
pentapeptide series. 
On the whole, the tetrapeptides displayed more balanced MOR and DOR binding with 
reduced selectivity relative to KOR. The two most promising ligands in this series, JH6 (JH 
compounds synthesized by Jeff Ho.) and JPAM13 (SMeS), both contained a homophenylalanine 
in the third position. These ligands were therefore modified with a C-terminal β-glucoserine, in 
which the side chain hydroxyl of Ser is covalently O-linked to a β-glucose, to improve 
blood/brain barrier penetration. Unfortunately, the effects of the modification are still somewhat 
unpredictable and the resulting ligands, JPAM18 (SEtS) and JPAM19 (SMeS), did not display 
the desired efficacy profile.  
It is worth noting that the size of the bridge between the two thiol containing side chains, 
methyl vs. ethyl, can have a profound impact upon the efficacy of the resulting ligands. 
Modeling studies suggest that the 2, 6 methyl groups on Dmt can rotate to form a steric clash 
with the dithioether linkage, depending on the size of the cycle and the bulk of the amino acid 
within the cyclized portion of the molecule. To relieve this clash the Dmt will rotate, expanding 
the overall profile of the molecule. This extended pose can prevent the ligand from fitting into 
the narrower active conformation of the opioid receptor binding pockets and reduce efficacy. 
Future work will include an exploration of how the addition of a C-terminal sugar moiety 
affects the efficacy profile of various peptide ligands and how linker length and sugar choice 
change these effects. Arginine and homo-arginine extensions will also be pursued as a means of 
improving bioavailability. We will also explore how Tyr
1
 replacements to promising sequences, 
such as JPAM11 or JPAM13, affect binding and efficacy. 
5.2.3 Linear Mixed Efficacy MOR/DOR Peptides 
 While we achieved success in developing cyclic mixed efficacy MOR/DOR ligands that 
displayed the desired binding and efficacy profile, there is still room for improvement. The 
yields on cyclic peptides are low and the cyclization process often produces side products, 
making purification difficult. As conformational restriction was initially introduced as a means to 
increase receptor specificity, we reasoned that linearized versions of our cyclic ligands might be 
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as successful as their cyclic counterparts, but with improved yields and greater ease of 
purification.  
 Two series of linear ligands were developed: direct translations of the cyclic tetrapeptides 
described above and modifications to the Roques scaffold of mixed efficacy MOR/DOR agonist 
peptides DTLET and DTLES [6, 17]. In both series we made various hydrophobic 
replacements; for our shorter pentapeptide translations we sought to reproduce our success with 
the cyclic tetrapeptides and for the longer more flexible Roques analogues we planned to add 
steric bulk to selectively reduce the DOR efficacy present in the parent ligands. 
 With only a few exceptions the direct linear translations of cyclic peptides displayed poor 
binding to MOR and DOR and no efficacy at any of the opioid receptors. As this series lacks the 
conformational restriction they adopt a more extended pose in the opioid binding site. This 
extended conformation is unable to fit into the relatively narrow active site of any of the opioid 
receptors, leading to antagonist behavior. It also forces these ligands to sit higher in the binding 
site of the inactive state of the receptor, preventing them from making necessary electrostatic 
contacts between the N-terminus and conserved residues in the binding site, lowering the affinity 
of this series for the opioid receptors in general. 
 The few exceptions to this trend were all able to adopt a more compact binding pose, 
lending them agonist character at MOR and/or DOR. VRP-35 (VRP compounds synthesized by 
Vanessa Porter) contains an Aci
3
, which is more constrained and closer to the backbone of the 
ligand than any other replacements in this series. VRP-35 is the only ligand in this series that 
displays the desired MOR agonist/DOR antagonist profile and the selective efficacy is likely due 
the conformational restriction introduced by the constrained Aci
3
. JPAM7 contains a Hfe
3
 
residue and displays full agonist behavior at DOR and partial agonist behavior at MOR. 
Modeling studies suggest that the added flexibility in the Hfe side chain allows the ligand to 
adopt a more compact binding pose that allows it to fit deep into the narrower active site of MOR 
and DOR. This likely accounts for the high affinity and agonist character of JPAM7 at DOR and 
MOR.  
Modeling studies suggest that the bulk of DThr
2
 in these linear pentapeptides produces a 
steric clash in the active site of the opioid receptors, such that these ligands bind preferentially to 
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the inactive conformation of the receptors, producing opioid antagonists. We therefore 
synthesized the DSer
2
 analogue of JPAM12, HVW-5 (HVW compounds synthesized by Helen 
Waldschmidt). This substitution did, in fact, rescue MOR efficacy, however the effect was not 
selective and HVW-5 also displays DOR agonism. Future work will likely include exploring the 
SAR of these DSer
2
 linear ligands in an effort to selectively reduce DOR efficacy. 
 The Roques compounds, DTLET and DTLES, display efficacy at both MOR and DOR 
and were used as templates for our series of hexapeptide mixed efficacy ligands. We made a 
series of analogues with various hydrophobic residues in the fourth position in an effort to 
selectively reduce DOR efficacy in a manner similar to our cyclic peptides described above. We 
achieved selective reduction of DOR efficacy in JPAM16 which contains an Idg in the fourth 
position, though this ligand displays poor binding to MOR and DOR. JPAM16 likely displays 
the desired efficacy profile because the Idg
4
 is somewhat constrained and can selectively produce 
a steric clash in the DOR active site. We next made a Dmt
1
 substitution expecting an 
improvement in the binding profile. The resulting ligand, JPAM17, displayed the desired 
binding profile, but no longer stimulated MOR. Modeling studies comparing JPAM16 and 
JPAM17 showed that if JPAM17 were forced to adopt the same compact conformation as 
JPAM16 the methyl groups on the Dmt
1
 of JPAM17 would clash with Idg
4
. To relieve this 
clash JPAM17 adopts a less compact conformation, which prevents it from binding to the 
narrower MOR active site, resulting in a MOR antagonist. This is a trend we have observed in 
our cyclic ligands as well. 
Our inability to selectively reduce DOR agonism to produce a MOR agonist/DOR 
antagonist compound is not as problematic as it first sounds, as a MOR agonist/DOR agonist 
profile is also desirable. We therefore took our best MOR/DOR agonist, VRP-39, and added a C-
terminal glucoserine, to produce HVW-2. This ligand binds tightly to MOR and DOR and 
displays selectivity relative to KOR. It is a full agonist at MOR and DOR and is a KOR 
antagonist. Future work will include carrying this ligand forward into in vivo assays to explore 





5.2.4 Co-Expression and Trafficking of MOR and DOR 
Literature precedent states that mixed efficacy MOR/DOR ligands are slower to produce 
tolerance and dependence than traditional MOR agonist opioid analgesics [2-7, 9, 18-20]. 
Studies have also shown that some mixed efficacy MOR/DOR ligands even display reduced 
addiction liability as compared to MOR agonist analgesics [7, 9, 19, 20]. While the exact 
mechanism by which DOR ligands alter MOR agonist pharmacology is unknown, it is likely that 
this phenomenon is linked to the trafficking of the opioid receptors. Upon exposure to agonist 
MOR is first desensitized, then internalized into intracellular vesicles, and finally recycled to the 
plasma membrane as re-sensitized receptor; internalization without recycling leads to reduced 
surface expression of active receptor, a cellular hallmark of tolerance [21-26]. It has been 
proposed that internalization of MOR is a key part of re-sensitization and leads to recycling of 
the sensitive receptor, increasing cell surface expression of functional opioid receptors [24-28].  
To explore the effects of DOR and DOR ligands on the trafficking of agonist stimulated 




] dermorphin, and a selective 
fluorescent DOR antagonist, Dmt-Tic-Lys(Cy5)-OH were generated. These ligands were used in 
conjunction with fluorescence confocal microscopy to monitor the trafficking of MOR and DOR 
in live cells. We demonstrated that we can observe the initial binding of fluorescent MOR 
agonist to MOR on the plasma membrane and its subsequent internalization by tracking the 
fluorescent signal from our ligand. Similarly, we can see the binding of fluorescent DOR 
antagonist to DOR on the plasma membrane, where the signal remains, as antagonists do not 
induce internalization. 
A live cell platform stably expressing unlabeled MOR and transiently expressing cyan 
fluorescent protein labeled DOR (CDOR) was developed to explore the effects of DOR and 
DOR ligands on the trafficking of MOR. The presence of CDOR in the same cells as MOR did 
not alter the trafficking of MOR after exposure to our selective fluorescent MOR agonist. 
Neither did the trafficking of CDOR change in the presence of MOR upon exposure to our 
selective fluorescent DOR antagonist. However, upon exposure to both ligands, cells that 




I propose that DOR antagonists exert their effects on MOR agonist potency and tolerance 
by encouraging a DOR receptor conformation that promotes the dissociation of G protein. DOR 
has a high basal turnover rate [29, 30] and MOR and DOR share a pool of G proteins and other 
signaling partners [31] freeing downstream effectors to stimulate, internalize and recycle MOR 
after exposure to MOR agonist. This increased trafficking produces greater cell surface 
expression of functional MOR [24-28], leading to improved MOR agonist potency and reduced 
development of tolerance to MOR agonists, trends observed with the co-administration of MOR 
agonists with DOR antagonists [15, 32-35]. 
Future work will include the development of live cell platforms to examine the 
differences in trafficking between MOR/DOR drug cocktails and MOR/DOR mixed efficacy 
ligands. These experiments will require the development of cells that express fluorescently 
tagged receptors, as multifunctional ligands will bind to both receptors and any fluorescent signal 
they produce will not discriminate between MOR and DOR. Additionally, the development of 
fluorescently tagged receptors will preclude the development of multiple fluorescently tagged 
ligands with specific pharmacological profiles, a task which is more difficult than it may initially 
seem (Chapter 4.2.1 and Appendix A). The use of fluorescently labeled receptors will allow for 
the exploration of biased MOR agonists with DOR antagonists, inverse agonists or biased 
agonists, for a fuller picture of how different ligand combinations effect receptor trafficking. 
5.3 Mixed Efficacy Ligands and Receptor Trafficking: What can we do? 
MOR agonist analgesics are widely used in the treatment of chronic and acute pain and 
are some of the most widely prescribed drugs on the market [36, 37]. Unfortunately, chronic use 
of opioid analgesics leads to the development of tolerance and dependence, features that 
complicate dosing regimens for patients and limit the clinical use of opioids; tolerance and 
dependence have also been linked to increased addiction liability and may contribute to the 
prevalence of opioid abuse [1, 38, 39]. It has been demonstrated that the co-administration of a 
MOR agonist with a DOR agonist or antagonist mitigates the development of these adverse 
neurochemical adaptations, without negatively affecting antinociceptive properties. As a result, 
the development of mixed efficacy ligands has been the subject of much research, as have the 
mechanisms by which DOR ligands affect MOR signaling and trafficking. 
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In this work I describe the successful rational design of mixed efficacy MOR agonist/ 
DOR antagonist and MOR agonist/DOR agonist peptide ligands and the development of tools to 
monitor the trafficking of MOR and DOR in live cells. Together these tools can be used to 
explore how cells expressing both receptors respond to mixed efficacy ligands and drug 
cocktails. This data can be correlated with parallel in vivo experiments to draw inferences about 
how changes in receptor trafficking patterns on the cellular level correspond to neurochemical 
adaptations or changes in animal behavior. A better understanding of the “how” and “why” of 
the development of tolerance to and dependence on MOR agonists will open the door for rational 
design of better opioid analgesics, this will allow us to better serve patients in need of pain relief 
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Failed Fluorescent Ligand Scaffolds 
A.1 Introduction 
 As discussed in Chapter 4, we have already achieved some success in designing potent, 
selective fluorescent opioid ligands for MOR and DOR for use with confocal microscopy. We 
have in hand the two most interesting and clinically relevant types of opioid ligands in our 




(Cy3)] dermorphin (A2; Table A.1), 
and a selective fluorescent DOR antagonist, Dmt-Tic-Lys(Cy5)-OH (A32; Table A.2).  We have 
demonstrated their viability as opioid receptor probes for fluorescence confocal microscopy in 
live cells. We have generated several other scaffolds in hopes of finding a selective, fluorescent 
MOR antagonist and a selective fluorescent DOR agonist. To date none of the ligands have 
proved to have sufficient affinity and selectivity profiles. (Ligands synthesized are described in 
Table A.1 and Table A.2.) While we are most interested in how a MOR agonist and a DOR 
antagonist affect the trafficking, sequestering, and recycling of opioid receptors, in order to fully 
explore the functional crosstalk between MOR and DOR ideally a full complement of MOR and 
DOR ligands would be used. The state of the receptor (agonist bound vs. antagonist bound) may 
affect the overall conformation of the receptor and its ability to dimerize. This, in turn, may 
affect the co-trafficking of receptors, the development of tolerance and dependence, or alter 
ligand potency and efficacy. While these studies can also be completed with fluorescently 
labeled receptors and unlabeled ligands we first sought to produce a full toolbox of fluorescent 
opioid ligands. 
A.2 Attempts to Complete the Fluorescent Ligand Toolbox 
A.2.1 Selective Fluorescent MOR Antagonists 
Our initial attempts to generate a selective, fluorescent MOR antagonist began with the 
selective cyclic MOR antagonist DTic-c(S-S)[Cys-Tyr-Nle-Thr-Pen]Thr-NH2 (TCTNP; Table 
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 side chains and is a derivative 
of CTAP [1]. TCTNP was then modified with a C-terminal Lys for fluorescent labeling, as a Cys 





. The resulting ligand TCTNPK (A13) was a relatively selective, potent MOR antagonist, 
however, when this compound was labeled with Cy5, the resulting compound, TCTNPK(Cy3) 
(A14) was insoluble and could not be tested. We next attempted modifications of DTic-
c(SS)[Cys-Tyr-Arg-Thr-Pen]Thr-NH2 (TCTAP; Table A.1) [1] in hopes that the added charge 
would increase solubility; this compound was initially avoided as the Arg
4
 residue can 
potentially be labeled instead of the C-terminal Lys. Both the L- and D-Lys modifications (A15 
and A17 respectively) displayed good affinity and moderate selectivity, however once labeled 
the selectivity for MOR over DOR was lost and the potency at MOR was decreased (Table A.1). 
These scaffolds were then abandoned as no further logical modification were easily made. 
There is literature precedent for taking existing peptide scaffolds and modifying them 
with unnatural amino acids to alter their selectivity or efficacy. Changes in charge and bulk at the 
first position of opioid peptides have been shown to alter the efficacy of the resulting ligand 
relative to that of the parent [2-7]. We next attempted to generate a MOR antagonist by 
incorporating unnatural amino acids into dermorphin, a selective potent MOR agonist.  It has 





] dermorphin, will generate a MOR antagonist with a similar binding profile 






] dermorphin with 3-
(2,6-dimethyl-4-hydroxyphenyl)propanoic acid (Dhp) we hoped to generate a selective MOR 
antagonist with a handle for fluorescent labeling. However, this modification decreased the 






] dermorphin (A7; Table A.1), to such an extent that the 














Table A.1: Selective MOR Agonists and Antagonists and their Fluorescent Derivatives 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate, except for those marked with *, where 
n=1. nt = not tested. 
 
MOR Ligands Sequence MOR 
MOR DOR KOR Efficacy
A1 [Lys7,Cys8] Dermorphin Tyr-DAla-Phe-Gly-
Tyr-Pro-Lys-Cys-NH2






A5 [Lys7, Cys(AF488)8] Tyr-DAla-Phe-Gly-
Dermorphin Tyr-Pro-Lys-Cys(AF488)-NH2
A6 [Lys7, Cys(BODTMRX)8] Tyr-DAla-Phe-Gly-
Dermorphin Tyr-Pro-Lys-Cys(BodTMRX)-NH2























0.4±0.03 240±60 240±140 Full
Full131±03.8± 1.8
11± 1 400±200 nt Full
Fullnt532±1383.5±0.5
1.6±0.5 383±140 nt Full
Fullnt37±10.45±0.04
310±2 >1000 nt nt
ntnt10±10.3±0.1
73±3 153±6 nt nt
Neutralnt82±203.6±2
3.1±0.6 540±90 nt Neutral
Partialnt30±2013±1.5
5±1 >1000 400±90 Neutral
ntntntnt
2±0.7 420±90 nt nt
ntnt160±2038±3
7±1 400±40 nt nt
ntnt>100052*
1.5±0.2 234±3 nt nt
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There are also reports that modifying residues of the endomorphin II scaffold, Tyr-Pro-
Phe-Phe-NH2, would generate a potent, selective MOR antagonist [9]. The resulting ligand – 
Dmt-Sar-Phe-D-2Nal-NH2 (A8; Table A.1) – displayed poor selectivity. We made several C-
terminal modifications for labeling purposes and the C-terminal DLys analogue displayed 
modest selectivity for MOR over DOR. Unfortunately, once the ligand was conjugated with the 
fluorescent dye, Cy5 (A12), the improved selectivity was lost and the scaffold was abandoned. 
As there is a dearth of selective, peptidic MOR antagonists, further attempts to generate a 
selective, fluorescent, peptidic MOR antagonist were put on hold. 
A.2.2 Selective Fluorescent DOR Agonists 
We attempted modifying the peptide Tyr-Tic-Phe-Phe-NH2 (TIPP), a potent selective 
DOR antagonist [10], with unnatural amino acids to generate a DOR agonist, by adding 
hydrophobic bulk to the first position. First we demonstrated that C-terminal modification of 
TIPP with an L- or DCys (A20 and A21) and L- or DLys (A23 and A25) afforded selective DOR 
antagonists. Subsequent labeling of the modified TIPP analogues with Cy3 or Cy5 (A22, A24, 
and A26) yielded selective DOR antagonists (Table A.2), demonstrating that C-terminal 
modifications of the TIPP scaffold were well tolerated. The Tyr
1
 of TIPP was then replaced with 
an 4’-[N-(2-napthalen-2-yl)ethyl)carboxamido] phenylalanine (Ncp) residue (A27; Table A.2), 
as added hydrophobic bulk at the first position has been reported to confer agonism to opioid 
peptides [2, 11]. Unfortunately, this replacement decreased the selectivity of the ligand 
significantly; additionally the use of 
Ncp did not confer full agonism. We 
also attempted Tyr
1
 replacement with 
4’[N-(hexyl) carboxamido] 
phenylaline] (Hcp) (A28) in the first 
position which has been reported to 
confer agonism to the TIPP scaffold 
[2]. Unfortunately the resulting 
ligand, Hcp-Tic-Phe-Phe-NH2 (A28), 




scaffold was subsequently abandoned.  
It has been well established that diallyl substitutions on the N-terminus of opioid peptides 
can confer antagonism [12]. We reasoned that removal the N,N-diallyl substitution from the 
selective DOR antagonist ICI 174864 (N,Ndiallyl-Tyr-Aib-Aib-Phe-Leu-OH), might generate a 
selective DOR agonist. We therefore generated a new ligand, YAAFK(Ac) (Tyr-Aib-Aib-Phe-
Lys(Ac)-OH; Table A.2), lacking the N-terminal allyl groups and replacing the Leu
5
 with an 
acetylated Lys as a handle of later fluorescent labeling – we chose to use an acetylated Lys as 
acetylation masks the charge on the ɛ amine of the Lys and would better mimic the electronics of 
the labeled peptide. Unfortunately, these changes greatly reduced both the affinity for DOR and 
selectivity relative to MOR, so this scaffold was also abandoned. Having explored most of the 
reported avenues for selective, peptidic DOR agonists and antagonists, the generation of a 
selective fluorescent DOR agonist was also put on hold. 
DOR Ligands Sequence DOR
MOR DOR KOR Efficacy
A20 TIPP-C Tyr-Tic-Phe-Phe-Cys-NH2 >1000 4.6±0.8 >10,000 Neutral
A21 TIPP-dC Tyr-Tic-Phe-Phe-DCys-NH2 >1000 4.6±0.3 >10,000 Neutral
A22 TIPP-dC(Cy5) Tyr-Tic-Phe-Phe-Dcys(Cy5)-NH2 >1,000 4.6±0.4 >10,000 Neutral
A23 TIPP-K Tyr-Tic-Phe-Phe-Lys-NH2 >1000 4.7±0.5 >10,000 Neutral
A24 TIPP-K(Cy3) Tyr-Tic-Phe-Phe-Cys-NH2 130±50 40±28 nt Neutral
A25 TIPP-dK Tyr-Tic-Phe-Phe-DLys-NH2 >1000 2.3±0.5 >1,000 Neutral
A26 TIPP-dK(Cy3) Tyr-Tic-Phe-Phe-DLys(Cy3)-NH2 >1,000 50±35 nt Neutral
A27 NIPPdK Ncp-Tic-Phe-Phe-DLys-NH2 62* 3* nt Partial
A28 HIPPdK Hcp-Tic-Phe-Phe-DLys-NH2 1.0±0.03 56±5 nt Neutral
A29 YAAFK(Ac) Tyr-Aib-Aib-Phe-Lys(Ac)-OH 24.0±0.8 14±6 nt nt
A30 Dmt-Tic-Lys-OH Dmt-Tic-Lys-OH >1,000 1.2±0.6 >10,000 Neutral
A31 Dmt-Tic-Lys(Cy3)-OH Dmt-Tic-Lys(Cy3)-OH >1,000 4.6±1.2 >1,000 Neutral
A32 Dmt-Tic-Lys(Cy5)-OH Dmt-Tic-Lys(Cy5)-OH >1,000 4.7±0.7 >1,000 Neutral
Binding (nM)
Table A.2: Selective DOR Agonists and Antagonists and their Fluorescent Derivatives 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 
expressed as mean ± SEM of three separate assays performed in duplicate, except for those marked with *, where 





Our efforts to generate a complete toolbox of MOR and DOR ligands have utilized 
literature precedents with various modifications for labeling, affinity, efficacy, and selectivity. 
Our major problem has been with the selectivity of the ligands, especially after labeling with a 
fluorophore. We have had some success using our homology models to predict the best site and 
stereochemistry of modifications for fluorophore labeling. We initially chose to use the Cy dyes 
as labels for our opioid ligands based on their excitation/emission spectra, extinction coefficient, 
and photostability; other fluorophores may be explored to determine if the affinity and selectivity 
of the labeled ligands can be improved while maintaining the desired label properties. With the 
correct label we may be able to rescue some of the ligands previously abandoned due to 
selectivity or affinity issues. 
 
A.4 Materials and Methods 
A.4.1 Materials 
All reagents and solvents were purchased from commercial sources and used without 
further purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. 
Louis, MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue 
culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). 
Radioactive compounds were purchased from Perkin-Elmer (Waltham, MA, USA). Peptide 
synthesis reagents, amino acids, and Rink resin were purchased from Advanced Chem Tech 
(Louisville, KY, USA). All other chemicals and ligands were from either Sigma-Aldrich (St. 
Louis, MO) or Fisher Scientific (Pittsburgh, PA).  
A.4.2 Solid Phase Peptide Synthesis 
Peptides were synthesized using standard solid phase Fmoc 
(fluorenylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Synthesizer (CS Bio 
Company, Menlo Park, CA, USA), using previously described protocols. [13] C-terminal amide 
peptides were synthesized using Rink resin, C-terminal acid peptides were synthesized using 













methyl-2-pyrrolidone (NMP) was used to remove the first Fmoc protecting group before 
synthesis and again to remove the Fmoc-protecting group after each coupling cycle. Coupling 
was performed using a four-fold excess of amino acid and a solution of 0.4 M 
hydroxybenzotriazole (HOBt) and O-benzotriazole- N, N, N ', N '-tetramethyl-
uroniumhexafluoro- phosphate (HBTU) in dimethylformamide (DMF), in the presence of 
diisopropylethylamine (DIEA). After the synthesis was complete, the resin was washed with 
NMP, then with dichloromethane, and dried under vacuum. Difficult couplings of the artificial 
amino acids Dmt, Dhp, Ncp, and Hcp were performed with coupling times lasting 4-16 hours. 
The peptides were cleaved from the resin and side-chain-protecting groups removed by treatment 
at room temperature for 2 h with a cleavage cocktail consisting of 9.5 mL trifluoroacetic (TFA) 
acid, 0.25 mL triisopropylsilane (TIS) and 0.25 mL H2O. The solution was concentrated in 
vacuo, and peptides were precipitated using cold, fresh diethylether. The filtered crude material 
was then purified using a Waters semipreparative HPLC (Waters Corporation, Milford, MA, 
USA) with a Vydac Protein and Peptide C18 column, using a linear gradient 10% Solvent B 
(0.1% TFA acid in acetonitrile) in Solvent A (0.1% TFA acid in water) to 60% Solvent B in 
Solvent A, at a rate of 1% per minute. The identity all peptides were determined ESI-MS 
performed on an Agilent Technologies LC/MS system using a 1200 Series LC and 6130 
Quadrupole LC/MS (Agilent Technologies, Santa Clara, CA, USA) in positive mode with 50–
100 µL injection volume and a linear gradient of 0% Solvent D (0.02% TFA and 0.1% acetic 
acid (AcOH) in acetonitrile) in Solvent C (0.02% TFA and 0.1% AcOH in water) to 60% Solvent 
D in Solvent C in 15 min. The purity of all peptides was determined using a Waters Alliance 
2690 Analytical HPLC (Waters Corporation, Milford, MA, USA) and Vydac Protein and Peptide 
C18 reverse phase column, using a linear gradient of 0–70% Solvent B in Solvent A at a rate of 
1% per minute. Linear peptides were purified to ≥ 95% purity by UV absorbance at 230 nm. 
A.4.3 Fluorescent Labeling 
The purified peptide was labeled with Cy3 or Cy5 maleimide or NHS ester (GE 
Healthcare) according to the manufacturer’s instructions using a ratio of 1.5:1 peptide to 
fluorophore. The labeled peptide was further purified via semi-preparative HPLC using a 5 
micron Vydac C18 column as described above. The potency and efficacy labeled ligands 
confirmed in radiolabeled [
3
H]DPN competition and [
35




A.4.4 Cell Lines and Mammalian Membrane Preparations  
C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid 
receptor [14] and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) 
opioid receptor [15] were used for all in vitro assays. Cells were grown to confluence at 37ºC in 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with 
ice cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). 
Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 
150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200xg for 3 min. The 
cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized with a 
Tissue Tearor (Biospec Products, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The 
homogenate was centrifuged at 20,000xg for 20 min at 4 C, and the pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The 
final pellet was resuspended in 50mM Tris-HCl and frozen in aliquots at -80ºC. Protein 
concentration was determined via Bradford assay using bovine serum albumin as the standard. 
A.4.5 Radioligand Binding Assays in Mammalian Membrane Preparations 
Opioid ligand-binding assays were performed using competitive displacement of 0.2 nM 
[
3
H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane preparations 
containing opioid receptors. The assay mixture, containing membrane suspension (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine, and various concentrations 
of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. 
The samples were rapidly filtered through Whatman GF/C filters  using a Brandel harvester 
(Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl buffer. The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, 
Waltham MA, USA). Nonspecific binding was determined using 10 μM naloxone. Ki values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
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data using GraphPad Prism version 5.01 for Windows. The results presented are the mean ± 
standard error from at least three separate assays performed in duplicate. 
A.4.6 Stimulation of [
35
S]GTPγS Binding in Mammalian Membrane Preparations 
Agonist stimulation of [
35
S] guanosine 5'-O-[gamma-thio]triphosphate ([
35
S]GTPγS, 
1250 Ci, 46.2TBq/mmol) binding was measured as described previously [16].  Briefly, 
membranes (10-20 μg of protein/tube) were incubated 1 h at room temperature in GTPγS buffer 
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [
35
S]GTPγS, 30 μM 
guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation 
of [
35





enkephalin  (DAMGO) at MOR, DPen
2,5
- enkephalin (DPDPE) at DOR, or U69,593 at KOR. 
The reaction was terminated by rapidly filtering through GF/C filters and washing ten times with 
GTPγS buffer, and retained radioactivity was measured as described above.  The results 
presented are the mean ± standard error from at least three separate assays performed in 
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The Minimal Functional Unit of the Mu Opioid Receptor is Monomeric 
B.1 Introduction 
As discussed in chapters 1 and 4 receptor homo- and heterodimerization has been used to 
explain the wide array of pharmacological responses displayed by opioid receptors [1-6]. It has 
been suggested that these oligomers regulate opioid ligand binding, the association of 
downstream signaling partners, amplification of signal, and even trafficking and expression of 
receptors [6-14]. It has even been proposed that oligomerization is necessary for normal opioid 
function and that opioid homo- and heterodimers are the native receptor state [15-21]. There 
exists a plethora of indirect evidence suggesting that opioid dimers or higher order oligomers 
occur [1, 4-6] and that these dimers explain the effects DOR and DOR ligands have on MOR 
agonist behavior [2, 22-24]. However these experiments rely on ensemble measurements and do 
not look directly at the association of individual receptors on the molecular level. Previous work 
in the GPCR field has shown that some Class A GPCRs are able to function as monomers and 
that oligomerization is not necessary for normal binding and signaling in all GPCR systems [26-
31]. These data raise questions about the necessity of oligomerization for opioid function and the 
role it plays in vivo. 
At the present time researchers are deeply divided on the issue of functional opioid 
receptor oligomerization. However, novel techniques now allow us to explore the minimal 
functional unit needed for signaling, the examination of which was previously below the 
detection limit. Using single molecule total internal reflection fluorescence microscopy (SM-
TIRF-M) and the fluorescent MOR ligands developed in chapter 4, single molecule binding 
events can be studied directly in isolated receptor systems using characterized selective 
fluorescent ligands, a feat which is impossible to accomplish in ensemble measurements. These 
data can then be compared to data collected from more natural systems and inferences drawn 
about opioid receptor function in vivo. In this chapter I will explore the functionality of
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 MORisolated systems to determine if a monomeric MOR is capable of normal signaling, as 
measured in vitro. (Please note: This work has already been published [32].) 
B.2 Characterization of Monomeric MOR 
B.2.1 Isolation of Purified MOR 
In order to study the binding of a single 
ligand to a single receptor we must first 
purify monomeric receptor and isolate it in 
a pseudo-membrane. A construct expressing 
yellow fluorescent protein (YFP) 
conjugated human MOR with His, FLAG, 
and HA tags for purification (YMOR; note 
the YFP was used in other experiments to 
monitor the location of MOR, additionally, 
the yellow color of YFP aided in locating 
the fractions containing receptor during purification; Figure B.1),  was expressed in Sf9 and 
HighFive
TM
 insect cells.  The potency and efficacy of DAMGO in membrane preparations of 
insect cells expressing YMOR was tested and was well in line with its observed pharmacological 
characteristics in mammalian cells expressing unlabeled human MOR [33]. We chose a high 
density lipoprotein (HDL) reconstitution system to isolate monomeric YMOR (Figure B.2), 
however reconstitution requires the purification of active receptor in large enough quantities for 
subsequent biochemical manipulation and analysis. Previous reports of MOR purification from 
endogenous or recombinant sources have yielded either low quantities [34-38] or poor agonist 
binding affinities [39-41]. We were able to successfully purify large quantities of active YMOR 
monomer [33]; several aspects were key to the expression and purification of YMOR: a 
cleavable hemagglutinin signal sequence at the receptor’s N-terminus [42], the presence of 
naltrexone during expression, and the inclusion of cholesteryl hemisuccinate and naltrexone 
during the entire purification process. These modifications contributed to the stabilization of 
YMOR, leading to an increase in yields during the chromatography process as well as increasing 
the specific activity of the detergent solubilized receptor [33].  (Plasmid design, expression 
systems, and purification techniques for YMOR developed by Adam Kuszak [32].) 




The purified YMOR was then reconstituted into the phospholipid bilayer of a HDL 
particle. The HDL particles are monodispersed, uniform in size, and preferentially incorporate a 
GPCR monomer; G proteins were also incorporated into these discs to assess the functionality of 
the isolated receptor [29, 33, 43].  The ability of the YMOR isolated in HDL discs to bind ligand 
and turn over G proteins was also characterized and shown to be within the normal range of 
unlabeled MOR expressed in mammalian systems (Table B.1) [33, 44-46].  Having generated a 
platform for testing purified, non-membrane bound MOR, we next needed to develop selective, 
fluorescent ligands as tools to confirm that the receptor was indeed in a monomeric state and to 
further characterize of the HDL disc bound receptor. 
Figure B.2: Schematic for the Incorporation of GPCRs into HDL Particles – Purified apo A1 protein is 
incubated with the lipids POPC and POPG and purified receptor in a solution containing detergent. Detergent 
is then removed using Biobeads ®. Upon detergent removal the apo A1 protein corrals lipids and receptor, 















0.4±0.3 2.1±0.3 Full 17.7±0.8 Full 23±3
Table B.1: Comparison of in vitro Binding and Efficacy for Dermorphin Derivatives in Membrane 
Preparations and HDL Particles 
Binding affinities (Ki) were obtained by competitive displacement of radiolabeled [
3
H] diprenorphine. Efficacy data 
were obtained using [
35
S] GTPγS binding assay. Efficacy is represented as percent maximal stimulation relative to 
standard agonists DAMGO (MOR), DPDPE (DOR) or U69,593 (KOR) at 10µM concentrations. All values are 




B.2.2 Selective Fluorescent MOR Ligands 
 In order to explore the individual ligand binding events via fluorescence microscopy, we 
must first develop selective, potent, fluorescent ligands for the receptor in question. Since we 
plan to explore the functionality of isolated MOR we need to develop a fluorescent MOR 





] dermorphin, which we can now use in our fluorescent microscopy 
experiments to study isolated MOR 
B.2.3 Single Molecule Photobleaching in HDL Particles 
 Having developed a 
selective fluorescent MOR 
ligand and a system in 
which to isolate MOR, we 
next sought to confirm that 
the YMOR isolated in HDL 
particles was in fact 
monomeric. Binding of a 
saturating concentration of 






dermorphin, to YMOR 
reconstituted in HDL discs 
was imaged with single molecule total internal reflection fluorescence microscopy (SM-TIRF-
M). Samples containing 50 pmolar receptor were continuously excited at 532 nm, the excitation 
wavelength of Cy3, and fluorescence intensity traces were analyzed for step-wise photo-
bleaching. Approximately 95% of the fluorescent traces exhibited single-step photo-bleaching, 





localized within each fluorescence focus. This would indicate that there is a single binding site 
located in each fluorescence foci, the corollary being that each foci contains a single receptor. 
This would mean that the HDL discs do indeed contain monomeric YMOR and that this receptor 
is fully functional in the monomeric state. 
Figure B.3: Photobleaching of Monomeric MOR – (A) Reconstituted 
HDL without receptor was incubated with fluorescent agonist. No significant 
binding was observed, indicating that the fluorescently labeled peptide has 
minimal non-specific binding. (B) HDL particles containing YMOR+Gi2 
were incubated with fluorescently labeled agonist. Significant binding was 
observed. (C) Representative single step photobleaching data. (D) 
Quantification of the number of traces with single and double step 





We have successfully isolated pure monomeric YMOR in HDL discs and designed 
selective, fluorescent opioid probes to explore the characteristics of these isolated receptors. We 
have demonstrated that these monomeric YMORs bind ligand and turn over G protein in a 
manner comparable to assays performed in membrane preparations or in vivo. [33] Although we 
have illustrated the functionality of monomeric MOR, these data do not preclude the existence of 
opioid receptor oligomerization in vitro or in vivo. It is possible that homo- and 
heterodimerization creates unique receptor conformations that may be subject to differential 
regulation, desensitization, and trafficking. HDL reconstitution of YMOR provided a platform 
for analysis of ligand binding using single molecule microscopy. In this study we examined the 




]dermorphin with SM-TIRF-M. 
To the best of our knowledge these data [33] represent the first reported observation of a peptide 
agonist binding to an isolated GPCR in a lipid bilayer using single molecule imaging.  
 
B.4 Materials and Methods 
B.4.1 Materials 
All reagents and solvents were purchased from commercial sources and used without 
further purification. All chemicals and biochemicals were purchased from Sigma Aldrich (St. 
Louis, MO, USA) or Fisher Scientific (Hudson, NH, USA), unless otherwise noted.  All tissue 
culture reagents were purchased from Gibco Life Sciences (Grand Island, NY, USA). 
Radioactive compounds were purchased from Perkin-Elmer (Waltham, MA, USA). Peptide 
synthesis reagents, amino acids, and Rink resin were purchased from Advanced Chem Tech 
(Louisville, KY, USA). Wang resins were purchased from Nova Biochem, EMD (Gibbstown, 
NJ, USA). G protein baculoviruses encoding rat Gαi2, His6-Gα1 and Gα2 were provided by Dr. 
Alfred G. Gilman (University of Texas Southwestern, Dallas, TX). DNA encoding human µ 
opioid receptor was generously provided by Dr. John R. Traynor (University of Michigan, Ann 





Baculovirus expression vectors and Sf900
TM
 Serum Free Medium were from Invitrogen 
(Carlsbad, CA). InsectExpress
TM
 medium was purchased from Lonza (Allendale, NJ). N-decyl-
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-D-maltoside was from Dojindo (Rockville, MD). All lipids were from Avanti Polar Lipids 
(Alabaster, AL). [
3




 NHS-Biotin reagent was from Pierce (Rockford, IL). Ovomucoid 
Trypsin Inhibitor was purchased from United States Biological (Swampscott, MA). All other 
chemicals and ligands were from either Sigma-Aldrich (St. Louis, MO) or Fisher Scientific 
(Pittsburgh, PA). GF/B and BA85 filters, Cy3 and Cy5 NHS-ester mono-reactive dyes, and 
Source15Q and Superdex200 chromatography resins were from GE Healthcare (Piscataway, NJ). 
Talon
TM
 resin was from Clontech (Mountain View, CA). BioBeads absorbant resin was from 
Bio-Rad (Hercules, CA). Chromatography columns were run using a BioLogic Duo-Flow 
Protein Purification System from Bio-Rad. Amicon Ultra centrifugation filters were from 
Millipore (Billerica, MA). Amino acids for ligand synthesis were obtained from Advanced 
ChemTech (Louisville, KY) or Sigma-Aldrich (St. Louis, MO). 
 B.4.2 [
3
H]DPN Saturation and Agonist Competition Binding Assays in HDL Particles 
Binding reactions were prepared in 100 µL volumes. Membrane fractions prepared from 
Sf9 or HighFive
TM
 cells expressing YMOR (0.5 to 5 µg total protein, prepared as above) were 
incubated with [
3
H]DPN (0.25 to 4 nM) for 1 hr at room temperature in 25 mM Tris pH 7.7, 136 
mM NaCl, 2.7 mM KCl (TBS) buffer.  Nonspecific binding was determined in the presence of 
20 µM (NTX). Bound [
3
H]DPN was separated from free by rapid filtration through GF/B filters 
and three 200 µL washes of ice cold TBS. [
3
H]DPN saturation binding reactions on YMOR 
incorporated into rHDL particles were prepared in TBS pH 7.7, 0.1% BSA and Sephadex G-50 
Fine (GE Healthcare) gravity-flow columns were used to separate bound from free [
3
H]DPN.  
Agonist competition assays in HDL particles were performed in 25 mM Tris pH 7.7, 5 mM 
NaCl, 0.1% BSA. [
3
H]DPN binding assays on detergent-solubilized YMOR were performed in 
50 mM Tris pH 8, 136 mM NaCl, 0.1% DDM, 0.01% CHS and separated on Sephadex G-50 
gravity flow columns. For agonist competition assays receptor samples were incubated with 0.5 
to 1 nM [
3
H]DPN and increasing concentrations of agonist (1 pM to 1 mM) in the absence or 
presence of 10 µM GTPS. Samples were measured for radioactivity on a liquid scintillation 
counter and data was fit to one-site saturation, one-site competition or two-site competition 






S]GTPS Binding Assay in HDL Particles 
One hundred µL volume reactions were prepared containing 1-10 µg total membrane protein 
from YMOR expressing HighFive
TM
 cells or ~80 fmoles of YMOR incorporated into rHDL 
particles in 30mM Tris pH 7.4, 100 mM NaCl, 5 mM MgCl2
(membranes or HDL particles), and 10 nM isotopically diluted [
35
were incubated with increasing concentrations of agonists (1 pM to 1 mM) for 1 hr at room 
temperature, then rapidly filtered through GF/B (membrane samples) or BA85 filters (HDL 
samples) and washed three times with 2 mL ice cold 30 mM Tris pH 7.4, 100 mM NaCl, 5 mM 
MgCl2. Samples were measured for radioactivity on a liquid scintillation counter and data was fit 
to a log dose-response model using Prism 5.0. 
B.4.4 Solid Phase Peptide Synthesis 
Peptides were synthesized using standard solid phase Fmoc 
(fluorenylmethyloxycarbonyl) chemistry on a CS Bio CS336X Peptide Synthesizer (CS Bio 
Company, Menlo Park, CA, USA), using previously described protocols. [47] C-terminal amide 
peptides were synthesized using Rink resin, C-terminal acid peptides were synthesized using 
Fmoc-Wang resin preloaded with the C-terminal amino acid. A 20% solution of piperidine in N-
methyl-2-pyrrolidone (NMP) was used to remove the first Fmoc protecting group before 
synthesis and again to remove the Fmoc-protecting group after each coupling cycle. Coupling 
was performed using a four-fold excess of amino acid and a solution of 0.4 M 
hydroxybenzotriazole (HOBt) and O-benzotriazole- N, N, N ', N '-tetramethyl-
uroniumhexafluoro- phosphate (HBTU) in dimethylformamide (DMF), in the presence of 
diisopropylethylamine (DIEA). After the synthesis was complete, the resin was washed with 
NMP, then with dichloromethane, and dried under vacuum. Difficult couplings of the artificial 
amino acids Dmt, Dhp, Ncp, and Hcp were performed with coupling times lasting 4-16 hours. 
The peptides were cleaved from the resin and side-chain-protecting groups removed by treatment 
at room temperature for 2 h with a cleavage cocktail consisting of 9.5 mL trifluoroacetic (TFA) 
acid, 0.25 mL triisopropylsilane (TIS) and 0.25 mL H2O. The solution was concentrated in 
vacuo, and peptides were precipitated using cold, fresh diethylether. The filtered crude material 
was then purified using a Waters semipreparative HPLC (Waters Corporation, Milford, MA, 
USA) with a Vydac Protein and Peptide C18 column, using a linear gradient 10% Solvent B 
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(0.1% TFA acid in acetonitrile) in Solvent A (0.1% TFA acid in water) to 60% Solvent B in 
Solvent A, at a rate of 1% per minute. The identity all peptides were determined ESI-MS 
performed on an Agilent Technologies LC/MS system using a 1200 Series LC and 6130 
Quadrupole LC/MS (Agilent Technologies, Santa Clara, CA, USA) in positive mode with 50–
100 µL injection volume and a linear gradient of 0% Solvent D (0.02% TFA and 0.1% acetic 
acid (AcOH) in acetonitrile) in Solvent C (0.02% TFA and 0.1% AcOH in water) to 60% Solvent 
D in Solvent C in 15 min. The purity of all peptides was determined using a Waters Alliance 
2690 Analytical HPLC (Waters Corporation, Milford, MA, USA) and Vydac Protein and Peptide 
C18 reverse phase column, using a linear gradient of 0–70% Solvent B in Solvent A at a rate of 
1% per minute. Linear peptides were purified to ≥ 95% purity by UV absorbance at 230 nm. 
B.4.5 Fluorescent Labeling 
The purified peptide was labeled with Cy3 or Cy5 maleimide or NHS ester (GE 
Healthcare) according to the manufacturer’s instructions using a ratio of 1.5:1 peptide to 
fluorophore. The labeled peptide was further purified via semi-preparative HPLC using a 5 
micron Vydac C18 column as described above. The potency and efficacy labeled ligands 
confirmed in radiolabeled [
3
H]DPN competition and [
35
S]GTPγS binding assays. 
B.4.6 Cell Lines and Mammalian Membrane Preparations  
C6-rat glioma cells stably transfected with a rat μ (C6-MOR) or rat δ (C6-DOR) opioid 
receptor [48] and Chinese hamster ovary (CHO) cells stably expressing a human κ (CHO-KOR) 
opioid receptor [49] were used for all in vitro assays. Cells were grown to confluence at 37ºC in 
5% CO2 in Dulbecco’s Modified Eagle’s Medium containing 10% fetal bovine serum and 5% 
penicillin/streptomycin. Membranes were prepared by washing confluent cells three times with 
ice cold phosphate-buffered saline (0.9% NaCl, 0.61 mM Na2HPO4, 0.38 mM KH2PO4, pH 7.4). 
Cells were detached from the plates by incubation in warm harvesting buffer (20 mM HEPES, 
150 mM NaCl, 0.68 mM EDTA, pH 7.4) and pelleted by centrifugation at 200xg for 3 min. The 
cell pellet was suspended in ice-cold 50 mM Tris-HCl buffer, pH 7.4 and homogenized with a 
Tissue Tearor (Biospec Products, Inc, Bartlesville, OK, USA) for 20 s at setting 4. The 
homogenate was centrifuged at 20,000xg for 20 min at 4 C, and the pellet was rehomogenized in 
50 mM Tris-HCl with a Tissue Tearor for 10 s at setting 2, followed by recentrifugation. The 
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final pellet was resuspended in 50mM Tris-HCl and frozen in aliquots at -80ºC. Protein 
concentration was determined via Bradford assay using bovine serum albumin as the standard. 
B.4.7 Radioligand Binding Assays in Mammalian Membrane Preparations 
Opioid ligand-binding assays were performed using competitive displacement of 0.2 nM 
[
3
H]diprenorphine (250 µCi, 1.85TBq/mmol) by the test compound from membrane preparations 
containing opioid receptors. The assay mixture, containing membrane suspension (20 μg 
protein/tube) in 50 mM Tris-HCl buffer (pH 7.4), [
3
H]diprenorphine, and various concentrations 
of test peptide, was incubated at room temperature for 1 h to allow binding to reach equilibrium. 
The samples were rapidly filtered through Whatman GF/C filters  using a Brandel harvester 
(Brandel, Gaithersburg, MD, USA) and washed three times with 50 mM Tris-HCl buffer. The 
radioactivity retained on dried filters was determined by liquid scintillation counting after 
saturation with EcoLume liquid scintillation cocktail in a Wallac 1450 MicroBeta (Perkin-Elmer, 
Waltham MA, USA). Nonspecific binding was determined using 10 μM naloxone. Ki values 
were calculated using nonlinear regression analysis to fit a logistic equation to the competition 
data using GraphPad Prism version 5.01 for Windows. The results presented are the mean ± 
standard error from at least three separate assays performed in duplicate. 
B.4.8 Stimulation of [
35
S]GTPγS Binding in Mammalian Membrane Preparations 
Agonist stimulation of [
35
S] guanosine 5'-O-[gamma-thio]triphosphate ([
35
S]GTPγS, 
1250 Ci, 46.2TBq/mmol) binding was measured as described previously [50].  Briefly, 
membranes (10-20 μg of protein/tube) were incubated 1 h at room temperature in GTPγS buffer 
(50 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, pH 7.4) containing 0.1 nM [
35
S]GTPγS, 30 μM 
guanosine diphosphate (GDP), and varying concentrations of test peptides. Peptide stimulation 
of [
35





enkephalin  (DAMGO) at MOR, DPen
2,5
- enkephalin (DPDPE) at DOR, or U69,593 at KOR. 
The reaction was terminated by rapidly filtering through GF/C filters and washing ten times with 
GTPγS buffer, and retained radioactivity was measured as described above.  The results 
presented are the mean ± standard error from at least three separate assays performed in 









]dermorphin binding to rHDL-YMOR+Gi2.  
Purified recombinant apoA-1 was biotinylated at a 4:1 molar ratio of biotin:apoA-1 using 
EZ-Link
TM
 NHS-Biotin (Pierce), according to the manufacturer’s protocol. Biotin-apoA-1 was 
separated from unconjugated biotin on a Superdex200 gel filtration column. Purified YMOR was 
then reconstituted with biotin-apoA-1, POPC, POPG, and brain lipid extract as above. Purified 
Gi2 heterotrimer was added to reconstituted receptor as above, and coupling was confirmed by 
observing high affinity competition of [
3





]dermorphin-Cy3 for 45 minutes at 
25
o
C in a 25 mM Tris pH 7.7. Samples were diluted 100-fold in 25 mM Tris and imaged as 
described above. Fluorophore intensity time-traces were collected for 30 to 100 seconds at 10 
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